Disease_ID;Disease;Entity1_type;Haplotype_ID;Haplotype;Entity2_type;LADME
PA445553;RHEUMATIC HEART DISEASE;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA445553;RHEUMATIC HEART DISEASE;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA445553;RHEUMATIC HEART DISEASE;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA443421;ARRHYTHMIAS, CARDIAC;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA443421;ARRHYTHMIAS, CARDIAC;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA443421;ARRHYTHMIAS, CARDIAC;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA443421;ARRHYTHMIAS, CARDIAC;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA443421;ARRHYTHMIAS, CARDIAC;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA443421;ARRHYTHMIAS, CARDIAC;DISEASE;PA165988484;CYP2D6*21;HAPLOTYPE;
PA443421;ARRHYTHMIAS, CARDIAC;DISEASE;PA165988488;CYP2D6*36;HAPLOTYPE;
PA166129534;TIME ABOVE THERAPEUTIC RANGE;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA166129534;TIME ABOVE THERAPEUTIC RANGE;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA166129534;TIME ABOVE THERAPEUTIC RANGE;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA444398;HEMATOMA, SUBDURAL;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA444398;HEMATOMA, SUBDURAL;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165816561;CYP2C9*33;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165816574;CYP2C9*30;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165816583;CYP2D6*17;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165948317;CYP2D6*9;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165948318;CYP2D6*29;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165949098;NAT2*4;HAPLOTYPE;PD
PA444552;HYPERTENSION;DISEASE;PA165949099;NAT2*5A;HAPLOTYPE;PD
PA444552;HYPERTENSION;DISEASE;PA165949138;NAT2*12A;HAPLOTYPE;PD
PA444552;HYPERTENSION;DISEASE;PA165951493;HLA-DRB1*04:01;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165971582;CYP2D6*31;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165971600;CYP2D6*46;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165981635;NAT2*6;HAPLOTYPE;PD
PA444552;HYPERTENSION;DISEASE;PA165981636;NAT2*7;HAPLOTYPE;PD
PA444552;HYPERTENSION;DISEASE;PA165981640;NAT2*14;HAPLOTYPE;PD
PA444552;HYPERTENSION;DISEASE;PA165988487;CYP2D6*35;HAPLOTYPE;
PA444552;HYPERTENSION;DISEASE;PA165988489;CYP2D6*45;HAPLOTYPE;
PA166124372;TREATMENT MODIFICATION;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA166124372;TREATMENT MODIFICATION;DISEASE;PA165819226;CYP3A4*8;HAPLOTYPE;
PA166124372;TREATMENT MODIFICATION;DISEASE;PA165819244;CYP3A4*20;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165819279;TPMT*9;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165819291;TPMT*21;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165948317;CYP2D6*9;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165971559;CYP2D6*7;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165971564;CYP2D6*11;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165971571;CYP2D6*20;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165984975;UGT2B15*1;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165984976;UGT2B15*2;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165988487;CYP2D6*35;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA165988488;CYP2D6*36;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA166005223;TPMT*32;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA166005224;TPMT*33;HAPLOTYPE;
PA166123366;EVENT-FREE SURVIVAL;DISEASE;PA166005225;TPMT*34;HAPLOTYPE;
PA166123755;DELAYED GRAFT FUNCTION;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;
PA166123755;DELAYED GRAFT FUNCTION;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA166123755;DELAYED GRAFT FUNCTION;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA166123755;DELAYED GRAFT FUNCTION;DISEASE;PA166128233;CYP3A5*6;HAPLOTYPE;
PA166123755;DELAYED GRAFT FUNCTION;DISEASE;PA166128234;CYP3A5*7;HAPLOTYPE;
PA166123755;DELAYED GRAFT FUNCTION;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;
PA443343;ANEMIA, HEMOLYTIC;DISEASE;PA165947826;G6PD B (REFERENCE);HAPLOTYPE;PD
PA443343;ANEMIA, HEMOLYTIC;DISEASE;PA165947827;G6PD A- 202A_376G;HAPLOTYPE;PD
PA443343;ANEMIA, HEMOLYTIC;DISEASE;PA165947830;G6PD MEDITERRANEAN HAPLOTYPE;HAPLOTYPE;PD
PA443343;ANEMIA, HEMOLYTIC;DISEASE;PA166121127;G6PD MEDITERRANEAN, DALLAS, PANAMA, SASSARI, CAGLIARI, BIRMINGHAM;HAPLOTYPE;PD
PA443343;ANEMIA, HEMOLYTIC;DISEASE;PA166121153;G6PD CANTON, TAIWAN-HAKKA, GIFU-LIKE, AGRIGENTO-LIKE;HAPLOTYPE;PD
PA443797;CORONARY DISEASE;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA443797;CORONARY DISEASE;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA443797;CORONARY DISEASE;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA166224501;EOSINOPHILIC ESOPHAGITIS;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA166224501;EOSINOPHILIC ESOPHAGITIS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA445019;MYOCARDIAL INFARCTION;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;PD
PA445019;MYOCARDIAL INFARCTION;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA445019;MYOCARDIAL INFARCTION;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA445019;MYOCARDIAL INFARCTION;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA445019;MYOCARDIAL INFARCTION;DISEASE;PA165980637;CYP2C19*4;HAPLOTYPE;
PA445019;MYOCARDIAL INFARCTION;DISEASE;PA165980638;CYP2C19*5;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA165988487;CYP2D6*35;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA443842;DEATH;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA166123431;HEART VALVE REPLACEMENT;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA166123431;HEART VALVE REPLACEMENT;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA166123431;HEART VALVE REPLACEMENT;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA166123431;HEART VALVE REPLACEMENT;DISEASE;PA165816554;CYP2C9*13;HAPLOTYPE;PD
PA166123431;HEART VALVE REPLACEMENT;DISEASE;PA165816555;CYP2C9*14;HAPLOTYPE;PD
PA444257;GASTROINTESTINAL NEOPLASMS;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA444257;GASTROINTESTINAL NEOPLASMS;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA444257;GASTROINTESTINAL NEOPLASMS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA444257;GASTROINTESTINAL NEOPLASMS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA444257;GASTROINTESTINAL NEOPLASMS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA444257;GASTROINTESTINAL NEOPLASMS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA445218;PANCREATIC NEOPLASMS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA445218;PANCREATIC NEOPLASMS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA445218;PANCREATIC NEOPLASMS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;PD
PA445218;PANCREATIC NEOPLASMS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;PD
PA445218;PANCREATIC NEOPLASMS;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA444607;INAPPROPRIATE ADH SYNDROME;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA444607;INAPPROPRIATE ADH SYNDROME;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;PD
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA165818757;CYP2B6*4;HAPLOTYPE;
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA165818760;CYP2B6*5;HAPLOTYPE;
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;PD
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA165818765;CYP2B6*7;HAPLOTYPE;
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA165818808;CYP2B6*18;HAPLOTYPE;
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;PD
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;PD
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;PD
PA445043;OPIOID-RELATED DISORDERS;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;PD
PA445042;NARCOLEPSY;DISEASE;PA165958103;HLA-DQB1*06:02;HAPLOTYPE;PD
PA444239;GALACTORRHEA;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA444239;GALACTORRHEA;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA444239;GALACTORRHEA;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA445850;THROMBOSIS;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA445850;THROMBOSIS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA445850;THROMBOSIS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA445850;THROMBOSIS;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA166128121;CARDIOTOXICITY;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA166128121;CARDIOTOXICITY;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA166128121;CARDIOTOXICITY;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA166128121;CARDIOTOXICITY;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA166128121;CARDIOTOXICITY;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA166128121;CARDIOTOXICITY;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA166128121;CARDIOTOXICITY;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA166128121;CARDIOTOXICITY;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166128121;CARDIOTOXICITY;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;PD
PA166128121;CARDIOTOXICITY;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;PD
PA166128121;CARDIOTOXICITY;DISEASE;PA166123321;CYP2D6*81;HAPLOTYPE;PD
PA447247;LIVER TRANSPLANTATION;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA447247;LIVER TRANSPLANTATION;DISEASE;PA165819240;CYP3A4*18;HAPLOTYPE;
PA447247;LIVER TRANSPLANTATION;DISEASE;PA165819244;CYP3A4*20;HAPLOTYPE;
PA447247;LIVER TRANSPLANTATION;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA447247;LIVER TRANSPLANTATION;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA447247;LIVER TRANSPLANTATION;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;
PA447247;LIVER TRANSPLANTATION;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA447247;LIVER TRANSPLANTATION;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA447247;LIVER TRANSPLANTATION;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA447247;LIVER TRANSPLANTATION;DISEASE;PA166128233;CYP3A5*6;HAPLOTYPE;PD
PA447247;LIVER TRANSPLANTATION;DISEASE;PA166128234;CYP3A5*7;HAPLOTYPE;PD
PA447247;LIVER TRANSPLANTATION;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;
PA445555;RHEUMATIC DISEASES;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA445555;RHEUMATIC DISEASES;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;
PA445555;RHEUMATIC DISEASES;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA165816524;CYP2C19*8;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA165816525;CYP2C19*9;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA165951131;HLA-DPB1*03:01;HAPLOTYPE;PD
PA443450;ASTHMA;DISEASE;PA165951133;HLA-DPB1*04:01;HAPLOTYPE;PD
PA443450;ASTHMA;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA165958686;CYP2C8*4;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA165959980;UGT1A3*1;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA165959981;UGT1A3*2;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA166048678;GSTT1 NULL;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA166048679;GSTT1 NON-NULL;HAPLOTYPE;
PA443450;ASTHMA;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165951340;HLA-DRB1*01:02;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165951348;HLA-DRB1*01:03;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165951511;HLA-DRB1*04:04;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165951669;HLA-DRB1*08:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165951757;HLA-DRB1*10:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165952269;HLA-DRB1*15:01;HAPLOTYPE;
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165953564;HLA-A*24:02;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954097;HLA-A*32:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954366;HLA-B*07:02;HAPLOTYPE;
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954643;HLA-B*13:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954649;HLA-B*13:02;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954745;HLA-B*15:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954769;HLA-B*15:02;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954778;HLA-B*15:05;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954787;HLA-B*15:11;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954792;HLA-B*15:12;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954793;HLA-B*15:13;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954809;HLA-B*15:21;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954811;HLA-B*15:24;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954812;HLA-B*15:25;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954816;HLA-B*15:27;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954823;HLA-B*15:32;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165954826;HLA-B*15:35;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165955274;HLA-B*35:10;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165955500;HLA-B*38:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165955505;HLA-B*38:02;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165955543;HLA-B*39:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165955559;HLA-B*39:05;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165955561;HLA-B*39:06;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165955565;HLA-B*39:09;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165955566;HLA-B*39:10;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165955628;HLA-B*40:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165956083;HLA-B*46:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165956201;HLA-B*51:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165956231;HLA-B*51:02;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165956366;HLA-B*52:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165956438;HLA-B*54:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165956463;HLA-B*55:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165956471;HLA-B*55:02;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165956528;HLA-B*56:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165956532;HLA-B*56:02;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165956537;HLA-B*56:06;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165956680;HLA-B*67:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165956686;HLA-B*78:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165957046;HLA-C*04:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165957085;HLA-C*04:03;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165957089;HLA-C*04:06;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165957090;HLA-C*04:07;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165957192;HLA-C*05:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165957217;HLA-C*05:09;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165958003;HLA-C*18:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165958103;HLA-DQB1*06:02;HAPLOTYPE;
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165958175;HLA-DQB1*03:02;HAPLOTYPE;
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165987830;HLA-B*57:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA165987831;HLA-B*58:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA166123427;HLA-A*02:01;HAPLOTYPE;PD
PA166120927;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS;DISEASE;PA166123429;HLA-B*48:01;HAPLOTYPE;
PA444823;LUPUS NEPHRITIS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA444823;LUPUS NEPHRITIS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165816583;CYP2D6*17;HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165818807;CYP2B6*9;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165948317;CYP2D6*9;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165980637;CYP2C19*4;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA166117146;SLC6A4 L ALLELE-RS25531T;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA166117147;SLC6A4 L ALLELE-RS25531C;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA166123321;CYP2D6*81;HAPLOTYPE;PD
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA447321;DEPRESSIVE DISORDER, MAJOR;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA443433;JUVENILE RHEUMATOID ARTHRITIS;DISEASE;PA165952269;HLA-DRB1*15:01;HAPLOTYPE;
PA444818;LUNG NEOPLASMS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA444818;LUNG NEOPLASMS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA444818;LUNG NEOPLASMS;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA444818;LUNG NEOPLASMS;DISEASE;PA166115865;UGT1A1*27;HAPLOTYPE;
PA445828;TESTICULAR NEOPLASMS;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;PD
PA445828;TESTICULAR NEOPLASMS;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;PD
PA447215;PSYCHOTIC DISORDER;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA447215;PSYCHOTIC DISORDER;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA447215;PSYCHOTIC DISORDER;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA447215;PSYCHOTIC DISORDER;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA447215;PSYCHOTIC DISORDER;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA447215;PSYCHOTIC DISORDER;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA447215;PSYCHOTIC DISORDER;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA447215;PSYCHOTIC DISORDER;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA447215;PSYCHOTIC DISORDER;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA447215;PSYCHOTIC DISORDER;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA447215;PSYCHOTIC DISORDER;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA447215;PSYCHOTIC DISORDER;DISEASE;PA166181185;CYP2D6*14;HAPLOTYPE;
PA162263525;NEUROPATHIC PAIN;DISEASE;PA165954769;HLA-B*15:02;HAPLOTYPE;
PA162263525;NEUROPATHIC PAIN;DISEASE;PA165954809;HLA-B*15:21;HAPLOTYPE;
PA166170245;FEBRILE NEUTROPENIA;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA166170245;FEBRILE NEUTROPENIA;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA166170245;FEBRILE NEUTROPENIA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA166170245;FEBRILE NEUTROPENIA;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA165816546;CYP2C9*5;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165816547;CYP2C9*6;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165816549;CYP2C9*8;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165816552;CYP2C9*11;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165816554;CYP2C9*13;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165816555;CYP2C9*14;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165816557;CYP2C9*16;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165816560;CYP2C9*31;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165816561;CYP2C9*33;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165816573;CYP2C9*29;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165924690;CYP2A6*1;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165924721;CYP2A6*4;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165951504;HLA-DRB1*04:03;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165952368;HLA-DRB1*16:02;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165952839;HLA-A*02:07;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165953358;HLA-A*11:01;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA165953622;HLA-A*24:07;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165954643;HLA-B*13:01;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165954649;HLA-B*13:02;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165954745;HLA-B*15:01;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA165954769;HLA-B*15:02;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA165954803;HLA-B*15:18;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165954807;HLA-B*15:19;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165954809;HLA-B*15:21;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165954816;HLA-B*15:27;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165955138;HLA-B*27:09;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165955461;HLA-B*37:01;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165955628;HLA-B*40:01;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165955651;HLA-B*40:02;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA165955913;HLA-B*44:03;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165956083;HLA-B*46:01;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165956139;HLA-B*48:04;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165956201;HLA-B*51:01;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165956231;HLA-B*51:02;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165956438;HLA-B*54:01;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165956674;HLA-B*59:01;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165956881;HLA-C*03:04;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165957428;HLA-C*07:04;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165958180;HLA-DQB1*03:03;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA165987831;HLA-B*58:01;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166048683;CYP2C9*37;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166048685;CYP2C9*39;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166048688;CYP2C9*42;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166048689;CYP2C9*43;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166048691;CYP2C9*45;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166048696;CYP2C9*50;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166048698;CYP2C9*52;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166048701;CYP2C9*55;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166117588;UGT1A4*1A;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166117589;UGT1A4*1B;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166117597;UGT1A4*2;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166117614;UGT1A6*1A;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA166117621;UGT1A6*2A;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA166117625;UGT1A6*3A;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA166117627;UGT1A6*4A;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA166117633;UGT1A6*8;HAPLOTYPE;PD
PA444065;EPILEPSY;DISEASE;PA166123425;HLA-C*03:02;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166123426;HLA-C*08:01;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166123427;HLA-A*02:01;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166123428;HLA-A*33:03;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA444065;EPILEPSY;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA165816583;CYP2D6*17;HAPLOTYPE;
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA165948317;CYP2D6*9;HAPLOTYPE;
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA165948318;CYP2D6*29;HAPLOTYPE;
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA166123332;CYP2D6*92;HAPLOTYPE;
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA166123337;CYP2D6*96;HAPLOTYPE;
PA447197;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY;DISEASE;PA166123455;CYP2D6*4XN;HAPLOTYPE;PD
PA444760;LEUKEMIA, MYELOID, ACUTE;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA444760;LEUKEMIA, MYELOID, ACUTE;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA445452;PSYCHOMOTOR AGITATION;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA445452;PSYCHOMOTOR AGITATION;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA445452;PSYCHOMOTOR AGITATION;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA445221;PANCYTOPENIA;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;PD
PA445221;PANCYTOPENIA;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;PD
PA445221;PANCYTOPENIA;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;PD
PA445221;PANCYTOPENIA;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;PD
PA445221;PANCYTOPENIA;DISEASE;PA165819279;TPMT*9;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165816583;CYP2D6*17;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165819240;CYP3A4*18;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165948317;CYP2D6*9;HAPLOTYPE;
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165958684;CYP2C8*2;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA165958686;CYP2C8*4;HAPLOTYPE;PD
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA166128233;CYP3A5*6;HAPLOTYPE;
PA445210;PAIN, POSTOPERATIVE;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;PD
PA447212;PANIC DISORDER;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA447212;PANIC DISORDER;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA447212;PANIC DISORDER;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA447212;PANIC DISORDER;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;PD
PA447212;PANIC DISORDER;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;PD
PA447264;HEPARIN-INDUCED THROMBOCYTOPENIA;DISEASE;PA165952388;HLA-DRB3*01:01;HAPLOTYPE;PD
PA166165020;ADVERSE CARDIOVASCULAR EVENTS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166165020;ADVERSE CARDIOVASCULAR EVENTS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA446051;VOMITING;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA446051;VOMITING;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA446051;VOMITING;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA446051;VOMITING;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA446051;VOMITING;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA446051;VOMITING;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA446051;VOMITING;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA446051;VOMITING;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA446051;VOMITING;DISEASE;PA165971588;CYP2D6*35XN;HAPLOTYPE;PD
PA446051;VOMITING;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA446051;VOMITING;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;PD
PA446051;VOMITING;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;PD
PA446051;VOMITING;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA446051;VOMITING;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA446051;VOMITING;DISEASE;PA166117621;UGT1A6*2A;HAPLOTYPE;
PA446051;VOMITING;DISEASE;PA166117639;UGT1A7*3;HAPLOTYPE;
PA446051;VOMITING;DISEASE;PA166123321;CYP2D6*81;HAPLOTYPE;PD
PA444485;HODGKIN DISEASE;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA444485;HODGKIN DISEASE;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA444516;HYPERCHOLESTEROLEMIA;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA444516;HYPERCHOLESTEROLEMIA;DISEASE;PA165819251;SLCO1B1*37;HAPLOTYPE;
PA444516;HYPERCHOLESTEROLEMIA;DISEASE;PA165819255;SLCO1B1*5;HAPLOTYPE;
PA444516;HYPERCHOLESTEROLEMIA;DISEASE;PA165819264;SLCO1B1*14;HAPLOTYPE;PD
PA444516;HYPERCHOLESTEROLEMIA;DISEASE;PA165819265;SLCO1B1*15;HAPLOTYPE;
PA444516;HYPERCHOLESTEROLEMIA;DISEASE;PA165981641;SLCO1B1*1;HAPLOTYPE;PD
PA444516;HYPERCHOLESTEROLEMIA;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;PD
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165819221;CYP3A4*3;HAPLOTYPE;PD
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165819240;CYP3A4*18;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165819244;CYP3A4*20;HAPLOTYPE;PD
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165819271;TPMT*3B;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165948045;CYP3A7*1A;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165948047;CYP3A7*1C;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;PD
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;PD
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA166128233;CYP3A5*6;HAPLOTYPE;PD
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA166128234;CYP3A5*7;HAPLOTYPE;PD
PA165817016;KIDNEY TRANSPLANTATION;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;PD
PA443459;ATRIAL FIBRILLATION;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA443459;ATRIAL FIBRILLATION;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA443459;ATRIAL FIBRILLATION;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA443459;ATRIAL FIBRILLATION;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA443459;ATRIAL FIBRILLATION;DISEASE;PA165816554;CYP2C9*13;HAPLOTYPE;PD
PA443459;ATRIAL FIBRILLATION;DISEASE;PA165816555;CYP2C9*14;HAPLOTYPE;PD
PA443459;ATRIAL FIBRILLATION;DISEASE;PA165816557;CYP2C9*16;HAPLOTYPE;
PA443459;ATRIAL FIBRILLATION;DISEASE;PA165860685;CYP4F2*1;HAPLOTYPE;
PA443459;ATRIAL FIBRILLATION;DISEASE;PA165860687;CYP4F2*3;HAPLOTYPE;
PA443459;ATRIAL FIBRILLATION;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA443459;ATRIAL FIBRILLATION;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA443459;ATRIAL FIBRILLATION;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA443459;ATRIAL FIBRILLATION;DISEASE;PA166128211;CYP2C9*60;HAPLOTYPE;
PA444745;LEPROSY;DISEASE;PA165954643;HLA-B*13:01;HAPLOTYPE;PD
PA445131;OBESITY;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA166159953;DOSE REDUCTION;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;PD
PA166159953;DOSE REDUCTION;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;PD
PA166159953;DOSE REDUCTION;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;PD
PA166159953;DOSE REDUCTION;DISEASE;PA165819271;TPMT*3B;HAPLOTYPE;PD
PA166159953;DOSE REDUCTION;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;PD
PA166159953;DOSE REDUCTION;DISEASE;PA165819279;TPMT*9;HAPLOTYPE;PD
PA443448;ASTHENIA;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA443448;ASTHENIA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA443448;ASTHENIA;DISEASE;PA166115844;UGT1A1*37;HAPLOTYPE;
PA445848;THROMBOEMBOLISM;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA445848;THROMBOEMBOLISM;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA445848;THROMBOEMBOLISM;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA445848;THROMBOEMBOLISM;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA157379134;MYALGIA;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA157379134;MYALGIA;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA166185626;SOMNOLENCE;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA166185626;SOMNOLENCE;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165816583;CYP2D6*17;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165818760;CYP2B6*5;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165818765;CYP2B6*7;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165819226;CYP3A4*8;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165819244;CYP3A4*20;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165819255;SLCO1B1*5;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165819265;SLCO1B1*15;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165924690;CYP2A6*1;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165924691;CYP2A6*46;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165924719;CYP2A6*2;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165924721;CYP2A6*4;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165924731;CYP2A6*7;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165924744;CYP2A6*17;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165924749;CYP2A6*20;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165924752;CYP2A6*23;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165924756;CYP2A6*26;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165948317;CYP2D6*9;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165948318;CYP2D6*29;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165951504;HLA-DRB1*04:03;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165953825;HLA-A*26:01;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165957658;HLA-C*08:02;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165958684;CYP2C8*2;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165958686;CYP2C8*4;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165971559;CYP2D6*7;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165971564;CYP2D6*11;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165971571;CYP2D6*20;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165980914;CYP2A6*9;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165980915;CYP2A6*12;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165980920;CYP2A6*35;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165981641;SLCO1B1*1;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165984975;UGT2B15*1;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165984976;UGT2B15*2;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165988484;CYP2D6*21;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA165988487;CYP2D6*35;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA165988488;CYP2D6*36;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA166123429;HLA-B*48:01;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA166123456;CYP2D6*10X2;HAPLOTYPE;PD
PA443560;BREAST NEOPLASMS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA166181185;CYP2D6*14;HAPLOTYPE;
PA443560;BREAST NEOPLASMS;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA165818753;CYP2B6*2;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA165818757;CYP2B6*4;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA165818770;CYP2B6*11;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165818788;CYP2B6*26;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA165818807;CYP2B6*9;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165818808;CYP2B6*18;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA165818812;CYP2B6*28;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165924719;CYP2A6*2;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165949098;NAT2*4;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA165949099;NAT2*5A;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA165949138;NAT2*12A;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA165951320;HLA-DRB1*01:01;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165951340;HLA-DRB1*01:02;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165952269;HLA-DRB1*15:01;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165952297;HLA-DRB1*15:03;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165954712;HLA-B*14:02;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165955215;HLA-B*35:01;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165955262;HLA-B*35:05;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165955628;HLA-B*40:01;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165956639;HLA-B*58:02;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165956805;HLA-C*02:10;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165957046;HLA-C*04:01;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165957658;HLA-C*08:02;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165958073;HLA-DQB1*05:01;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165958103;HLA-DQB1*06:02;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165958105;HLA-DQB1*06:03;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165958117;HLA-DQB1*06:09;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165958158;HLA-DQB1*02:01;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165958175;HLA-DQB1*03:02;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165958180;HLA-DQB1*03:03;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA165981635;NAT2*6;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA165981636;NAT2*7;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA165987830;HLA-B*57:01;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA165987831;HLA-B*58:01;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA166115843;UGT1A1*36;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA166115844;UGT1A1*37;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA166117278;CYP2B6*38;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA166117680;UGT1A9*3A;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA166123425;HLA-C*03:02;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA166123426;HLA-C*08:01;HAPLOTYPE;
PA447230;HIV INFECTIONS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA166128233;CYP3A5*6;HAPLOTYPE;PD
PA447230;HIV INFECTIONS;DISEASE;PA166128234;CYP3A5*7;HAPLOTYPE;PD
PA166114457;LUNG TRANSPLANTATION;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA166114457;LUNG TRANSPLANTATION;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA166114457;LUNG TRANSPLANTATION;DISEASE;PA165819240;CYP3A4*18;HAPLOTYPE;
PA166114457;LUNG TRANSPLANTATION;DISEASE;PA165819244;CYP3A4*20;HAPLOTYPE;
PA166114457;LUNG TRANSPLANTATION;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166114457;LUNG TRANSPLANTATION;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA166114457;LUNG TRANSPLANTATION;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA166114457;LUNG TRANSPLANTATION;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA166114457;LUNG TRANSPLANTATION;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA166114457;LUNG TRANSPLANTATION;DISEASE;PA166128233;CYP3A5*6;HAPLOTYPE;PD
PA166114457;LUNG TRANSPLANTATION;DISEASE;PA166128234;CYP3A5*7;HAPLOTYPE;PD
PA166129521;SEDATION;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA166129521;SEDATION;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA166129521;SEDATION;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA166129521;SEDATION;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA166129521;SEDATION;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA166129521;SEDATION;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA166129521;SEDATION;DISEASE;PA165816583;CYP2D6*17;HAPLOTYPE;
PA166129521;SEDATION;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA166129521;SEDATION;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA166129521;SEDATION;DISEASE;PA165948317;CYP2D6*9;HAPLOTYPE;
PA166129521;SEDATION;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;
PA160680212;LYMPHOMA, LARGE B-CELL, DIFFUSE;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA443362;ANGINA PECTORIS;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA443362;ANGINA PECTORIS;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA443362;ANGINA PECTORIS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA443362;ANGINA PECTORIS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA443362;ANGINA PECTORIS;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA443362;ANGINA PECTORIS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA443362;ANGINA PECTORIS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA444845;LYMPHOMA, NON-HODGKIN;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA444845;LYMPHOMA, NON-HODGKIN;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA444845;LYMPHOMA, NON-HODGKIN;DISEASE;PA165818813;CYP2B6*29;HAPLOTYPE;
PA444845;LYMPHOMA, NON-HODGKIN;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA444845;LYMPHOMA, NON-HODGKIN;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA444845;LYMPHOMA, NON-HODGKIN;DISEASE;PA166117272;CYP2B6*30;HAPLOTYPE;
PA444845;LYMPHOMA, NON-HODGKIN;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA444845;LYMPHOMA, NON-HODGKIN;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA445301;PERIPHERAL NERVOUS SYSTEM DISEASES;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA445301;PERIPHERAL NERVOUS SYSTEM DISEASES;DISEASE;PA165819226;CYP3A4*8;HAPLOTYPE;
PA445301;PERIPHERAL NERVOUS SYSTEM DISEASES;DISEASE;PA165819244;CYP3A4*20;HAPLOTYPE;
PA445301;PERIPHERAL NERVOUS SYSTEM DISEASES;DISEASE;PA165958684;CYP2C8*2;HAPLOTYPE;PD
PA445301;PERIPHERAL NERVOUS SYSTEM DISEASES;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;PD
PA445301;PERIPHERAL NERVOUS SYSTEM DISEASES;DISEASE;PA165958686;CYP2C8*4;HAPLOTYPE;PD
PA445301;PERIPHERAL NERVOUS SYSTEM DISEASES;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA445301;PERIPHERAL NERVOUS SYSTEM DISEASES;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA445301;PERIPHERAL NERVOUS SYSTEM DISEASES;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;PD
PA446861;HEPATITIS, AUTOIMMUNE;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA446861;HEPATITIS, AUTOIMMUNE;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA443626;CARCINOMA, SQUAMOUS CELL;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA443626;CARCINOMA, SQUAMOUS CELL;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166128365;BONE DENSITY;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;PD
PA166128365;BONE DENSITY;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;PD
PA447054;STROKE;DISEASE;PA165816522;CYP2C19*6;HAPLOTYPE;PD
PA447054;STROKE;DISEASE;PA165816524;CYP2C19*8;HAPLOTYPE;PD
PA447054;STROKE;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;PD
PA447054;STROKE;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA447054;STROKE;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA447054;STROKE;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA447054;STROKE;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA447054;STROKE;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA447054;STROKE;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA447054;STROKE;DISEASE;PA165980637;CYP2C19*4;HAPLOTYPE;PD
PA447054;STROKE;DISEASE;PA165980638;CYP2C19*5;HAPLOTYPE;PD
PA444447;HEPATOCELLULAR CARCINOMA;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;PD
PA444447;HEPATOCELLULAR CARCINOMA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;PD
PA444684;KIDNEY FAILURE, CHRONIC;DISEASE;PA165987831;HLA-B*58:01;HAPLOTYPE;
PA444684;KIDNEY FAILURE, CHRONIC;DISEASE;PA166123425;HLA-C*03:02;HAPLOTYPE;
PA444684;KIDNEY FAILURE, CHRONIC;DISEASE;PA166123428;HLA-A*33:03;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165949098;NAT2*4;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165949099;NAT2*5A;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165951968;HLA-DRB1*13:01;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165951978;HLA-DRB1*13:02;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165952289;HLA-DRB1*15:02;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165952839;HLA-A*02:07;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165953358;HLA-A*11:01;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165953564;HLA-A*24:02;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165953622;HLA-A*24:07;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165954243;HLA-A*68:01;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165954348;HLA-A*74:01;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165954366;HLA-B*07:02;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165954547;HLA-B*08:01;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165954643;HLA-B*13:01;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165954769;HLA-B*15:02;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165954787;HLA-B*15:11;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165954809;HLA-B*15:21;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165955215;HLA-B*35:01;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165955628;HLA-B*40:01;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165956083;HLA-B*46:01;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165956201;HLA-B*51:01;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165956532;HLA-B*56:02;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165956674;HLA-B*59:01;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165956704;HLA-C*01:02;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165956881;HLA-C*03:04;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165957448;HLA-C*07:18;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165958077;HLA-DQB1*05:02;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165958117;HLA-DQB1*06:09;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165958162;HLA-DQB1*02:02;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165958180;HLA-DQB1*03:03;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165981634;NAT2*5;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165981635;NAT2*6;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165981636;NAT2*7;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165981640;NAT2*14;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA165987831;HLA-B*58:01;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA166123425;HLA-C*03:02;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA166123427;HLA-A*02:01;HAPLOTYPE;PD
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA166123428;HLA-A*33:03;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA166123429;HLA-B*48:01;HAPLOTYPE;
PA166120929;SEVERE CUTANEOUS ADVERSE REACTIONS;DISEASE;PA166123430;HLA-DRB1*03:01;HAPLOTYPE;PD
PA446827;HEMATOLOGIC NEOPLASMS;DISEASE;PA165951734;HLA-DRB1*09:01;HAPLOTYPE;
PA446827;HEMATOLOGIC NEOPLASMS;DISEASE;PA165952135;HLA-DRB1*14:01;HAPLOTYPE;
PA446827;HEMATOLOGIC NEOPLASMS;DISEASE;PA166123426;HLA-C*08:01;HAPLOTYPE;
PA446827;HEMATOLOGIC NEOPLASMS;DISEASE;PA166123429;HLA-B*48:01;HAPLOTYPE;
PA166163391;STATIN-RELATED MYOPATHY;DISEASE;PA165819255;SLCO1B1*5;HAPLOTYPE;PD
PA166163391;STATIN-RELATED MYOPATHY;DISEASE;PA165819265;SLCO1B1*15;HAPLOTYPE;PD
PA166163391;STATIN-RELATED MYOPATHY;DISEASE;PA165981641;SLCO1B1*1;HAPLOTYPE;PD
PA443672;TRANSIENT ISCHEMIC ATTACK;DISEASE;PA165816522;CYP2C19*6;HAPLOTYPE;PD
PA443672;TRANSIENT ISCHEMIC ATTACK;DISEASE;PA165816524;CYP2C19*8;HAPLOTYPE;PD
PA443672;TRANSIENT ISCHEMIC ATTACK;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;PD
PA443672;TRANSIENT ISCHEMIC ATTACK;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA443672;TRANSIENT ISCHEMIC ATTACK;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA443672;TRANSIENT ISCHEMIC ATTACK;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA443672;TRANSIENT ISCHEMIC ATTACK;DISEASE;PA165980637;CYP2C19*4;HAPLOTYPE;PD
PA443672;TRANSIENT ISCHEMIC ATTACK;DISEASE;PA165980638;CYP2C19*5;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165818757;CYP2B6*4;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165818760;CYP2B6*5;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165818808;CYP2B6*18;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA165818809;CYP2B6*22;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924690;CYP2A6*1;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924691;CYP2A6*46;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924717;CYP2A6*1X2;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924719;CYP2A6*2;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924721;CYP2A6*4;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924731;CYP2A6*7;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924735;CYP2A6*10;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924736;CYP2A6*11;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924740;CYP2A6*13;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924741;CYP2A6*14;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924742;CYP2A6*15;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924744;CYP2A6*17;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924748;CYP2A6*19;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924749;CYP2A6*20;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924752;CYP2A6*23;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924753;CYP2A6*24;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924755;CYP2A6*25;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924756;CYP2A6*26;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924757;CYP2A6*27;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165924758;CYP2A6*28;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA165980914;CYP2A6*9;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165980915;CYP2A6*12;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA165980920;CYP2A6*35;HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;PD
PA445876;TOBACCO USE DISORDER;DISEASE;PA166117264;CYP2A6*38;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA166117265;CYP2A6*39;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA166117267;CYP2A6*41;HAPLOTYPE;
PA445876;TOBACCO USE DISORDER;DISEASE;PA166309214;CYP2A6*55;HAPLOTYPE;
PA166048926;LEAD POISONING, NERVOUS SYSTEM, CHILDHOOD;DISEASE;PA165947826;G6PD B (REFERENCE);HAPLOTYPE;PD
PA166048926;LEAD POISONING, NERVOUS SYSTEM, CHILDHOOD;DISEASE;PA165947827;G6PD A- 202A_376G;HAPLOTYPE;PD
PA444329;GRAVES DISEASE;DISEASE;PA165951282;HLA-DQA1*01:03;HAPLOTYPE;PD
PA444329;GRAVES DISEASE;DISEASE;PA165951678;HLA-DRB1*08:03;HAPLOTYPE;PD
PA444329;GRAVES DISEASE;DISEASE;PA165955505;HLA-B*38:02;HAPLOTYPE;PD
PA444329;GRAVES DISEASE;DISEASE;PA165955543;HLA-B*39:01;HAPLOTYPE;PD
PA444329;GRAVES DISEASE;DISEASE;PA165958097;HLA-DQB1*06:01;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA165819279;TPMT*9;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA165819291;TPMT*21;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA165958684;CYP2C8*2;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA165958686;CYP2C8*4;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA166005224;TPMT*33;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA166005225;TPMT*34;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA445113;NEUTROPENIA;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA445113;NEUTROPENIA;DISEASE;PA166048678;GSTT1 NULL;HAPLOTYPE;
PA445113;NEUTROPENIA;DISEASE;PA166048679;GSTT1 NON-NULL;HAPLOTYPE;
PA445113;NEUTROPENIA;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA166115844;UGT1A1*37;HAPLOTYPE;
PA445113;NEUTROPENIA;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA166117636;UGT1A7*1A;HAPLOTYPE;
PA445113;NEUTROPENIA;DISEASE;PA166117638;UGT1A7*2;HAPLOTYPE;
PA445113;NEUTROPENIA;DISEASE;PA166117639;UGT1A7*3;HAPLOTYPE;
PA445113;NEUTROPENIA;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA166131619;NUDT15*1;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA166131620;NUDT15*2;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA166131621;NUDT15*3;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA166131623;NUDT15*5;HAPLOTYPE;
PA445113;NEUTROPENIA;DISEASE;PA166151814;NUDT15*6;HAPLOTYPE;PD
PA445113;NEUTROPENIA;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;PD
PA445451;PSORIASIS;DISEASE;PA165957286;HLA-C*06:02;HAPLOTYPE;PD
PA166048814;HYPERURICEMIA;DISEASE;PA165987831;HLA-B*58:01;HAPLOTYPE;
PA166048814;HYPERURICEMIA;DISEASE;PA166121127;G6PD MEDITERRANEAN, DALLAS, PANAMA, SASSARI, CAGLIARI, BIRMINGHAM;HAPLOTYPE;
PA443286;ADRENAL HYPERPLASIA, CONGENITAL;DISEASE;PA165948045;CYP3A7*1A;HAPLOTYPE;
PA443286;ADRENAL HYPERPLASIA, CONGENITAL;DISEASE;PA165948047;CYP3A7*1C;HAPLOTYPE;
PA166163563;HIGH ON-TREATMENT PLATELET REACTIVITY;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166163563;HIGH ON-TREATMENT PLATELET REACTIVITY;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA166163563;HIGH ON-TREATMENT PLATELET REACTIVITY;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA445992;URINARY TRACT INFECTIONS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA445992;URINARY TRACT INFECTIONS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA134850491;TRANSPLANTATION;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA134850491;TRANSPLANTATION;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;PD
PA134850491;TRANSPLANTATION;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;PD
PA134850491;TRANSPLANTATION;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;PD
PA134850491;TRANSPLANTATION;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;PD
PA134850491;TRANSPLANTATION;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA134850491;TRANSPLANTATION;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA134850491;TRANSPLANTATION;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA443355;ANEMIA, SICKLE CELL;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA443355;ANEMIA, SICKLE CELL;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA443355;ANEMIA, SICKLE CELL;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA443355;ANEMIA, SICKLE CELL;DISEASE;PA165816583;CYP2D6*17;HAPLOTYPE;
PA443355;ANEMIA, SICKLE CELL;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA443355;ANEMIA, SICKLE CELL;DISEASE;PA165971594;CYP2D6*40;HAPLOTYPE;
PA443523;BLOOD COAGULATION DISORDERS;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA443523;BLOOD COAGULATION DISORDERS;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA444840;LYMPHOMA;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA444840;LYMPHOMA;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA443557;BRAIN NEOPLASMS;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA443557;BRAIN NEOPLASMS;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA443557;BRAIN NEOPLASMS;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA165818760;CYP2B6*5;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA165988484;CYP2D6*21;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA165988488;CYP2D6*36;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA166123456;CYP2D6*10X2;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA166127658;RECURRENCE FREE SURVIVAL;DISEASE;PA166181185;CYP2D6*14;HAPLOTYPE;
PA444368;HEART DISEASES;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA444368;HEART DISEASES;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA444368;HEART DISEASES;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA444368;HEART DISEASES;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA444368;HEART DISEASES;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA444368;HEART DISEASES;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA444368;HEART DISEASES;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA444368;HEART DISEASES;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA444368;HEART DISEASES;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA444368;HEART DISEASES;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA446615;RHABDOMYOSARCOMA, ALVEOLAR;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA166179129;EXACERBATION OF ASTHMA;DISEASE;PA166048678;GSTT1 NULL;HAPLOTYPE;
PA166179129;EXACERBATION OF ASTHMA;DISEASE;PA166048679;GSTT1 NON-NULL;HAPLOTYPE;
PA445190;OSTEOPOROSIS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA445190;OSTEOPOROSIS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA445204;OVARIAN NEOPLASMS;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;PD
PA445204;OVARIAN NEOPLASMS;DISEASE;PA165819226;CYP3A4*8;HAPLOTYPE;PD
PA445204;OVARIAN NEOPLASMS;DISEASE;PA165819244;CYP3A4*20;HAPLOTYPE;PD
PA445204;OVARIAN NEOPLASMS;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;
PA445204;OVARIAN NEOPLASMS;DISEASE;PA165987830;HLA-B*57:01;HAPLOTYPE;
PA445204;OVARIAN NEOPLASMS;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA445204;OVARIAN NEOPLASMS;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA445204;OVARIAN NEOPLASMS;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;PD
PA445204;OVARIAN NEOPLASMS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA445204;OVARIAN NEOPLASMS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA445204;OVARIAN NEOPLASMS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA445204;OVARIAN NEOPLASMS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA447325;CORONARY RESTENOSIS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA447325;CORONARY RESTENOSIS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA445428;PROTEIN DEFICIENCY;DISEASE;PA165947826;G6PD B (REFERENCE);HAPLOTYPE;PD
PA445428;PROTEIN DEFICIENCY;DISEASE;PA165947827;G6PD A- 202A_376G;HAPLOTYPE;PD
PA446304;LYMPHOMA, B-CELL;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA446304;LYMPHOMA, B-CELL;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA166123368;SCHIZOAFFECTIVE DISORDER;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA166123368;SCHIZOAFFECTIVE DISORDER;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA166123368;SCHIZOAFFECTIVE DISORDER;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA166123368;SCHIZOAFFECTIVE DISORDER;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA166123368;SCHIZOAFFECTIVE DISORDER;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA166123368;SCHIZOAFFECTIVE DISORDER;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA166123368;SCHIZOAFFECTIVE DISORDER;DISEASE;PA165819184;CYP1A2*7;HAPLOTYPE;
PA166123368;SCHIZOAFFECTIVE DISORDER;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA166123368;SCHIZOAFFECTIVE DISORDER;DISEASE;PA165955500;HLA-B*38:01;HAPLOTYPE;
PA166123368;SCHIZOAFFECTIVE DISORDER;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166123368;SCHIZOAFFECTIVE DISORDER;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA166123368;SCHIZOAFFECTIVE DISORDER;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA166152644;SCHIZENCEPHALY;DISEASE;PA165954769;HLA-B*15:02;HAPLOTYPE;
PA444460;HEROIN DEPENDENCE;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA444460;HEROIN DEPENDENCE;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA444460;HEROIN DEPENDENCE;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA444460;HEROIN DEPENDENCE;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA444460;HEROIN DEPENDENCE;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA444460;HEROIN DEPENDENCE;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA444460;HEROIN DEPENDENCE;DISEASE;PA165818757;CYP2B6*4;HAPLOTYPE;
PA444460;HEROIN DEPENDENCE;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA444460;HEROIN DEPENDENCE;DISEASE;PA165818808;CYP2B6*18;HAPLOTYPE;
PA444460;HEROIN DEPENDENCE;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;PD
PA444460;HEROIN DEPENDENCE;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;PD
PA443685;UTERINE CERVICAL NEOPLASMS;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA443685;UTERINE CERVICAL NEOPLASMS;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA444859;MALARIA;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA444859;MALARIA;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA444859;MALARIA;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA444859;MALARIA;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA444859;MALARIA;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA444859;MALARIA;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA444859;MALARIA;DISEASE;PA165947826;G6PD B (REFERENCE);HAPLOTYPE;PD
PA444859;MALARIA;DISEASE;PA165947827;G6PD A- 202A_376G;HAPLOTYPE;PD
PA444859;MALARIA;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA444859;MALARIA;DISEASE;PA165948317;CYP2D6*9;HAPLOTYPE;
PA444859;MALARIA;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA444859;MALARIA;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA444859;MALARIA;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA444370;HEART FAILURE;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA444370;HEART FAILURE;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA444370;HEART FAILURE;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA444370;HEART FAILURE;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA444370;HEART FAILURE;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA444370;HEART FAILURE;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA444370;HEART FAILURE;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA444370;HEART FAILURE;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA445802;TACHYCARDIA;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA445802;TACHYCARDIA;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA445802;TACHYCARDIA;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA445802;TACHYCARDIA;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA445802;TACHYCARDIA;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA445802;TACHYCARDIA;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA445802;TACHYCARDIA;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA445802;TACHYCARDIA;DISEASE;PA165988488;CYP2D6*36;HAPLOTYPE;
PA445802;TACHYCARDIA;DISEASE;PA166123321;CYP2D6*81;HAPLOTYPE;PD
PA444320;GRAFT VS HOST DISEASE;DISEASE;PA166048678;GSTT1 NULL;HAPLOTYPE;
PA444320;GRAFT VS HOST DISEASE;DISEASE;PA166048679;GSTT1 NON-NULL;HAPLOTYPE;
PA444320;GRAFT VS HOST DISEASE;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA444320;GRAFT VS HOST DISEASE;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA444250;GASTRITIS;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA444250;GASTRITIS;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA443460;ATRIAL FLUTTER;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA443460;ATRIAL FLUTTER;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA165817398;MYELOSUPPRESSION;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;PD
PA165817398;MYELOSUPPRESSION;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;PD
PA165817398;MYELOSUPPRESSION;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;PD
PA165817398;MYELOSUPPRESSION;DISEASE;PA165819271;TPMT*3B;HAPLOTYPE;PD
PA165817398;MYELOSUPPRESSION;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;PD
PA165817398;MYELOSUPPRESSION;DISEASE;PA165819276;TPMT*6;HAPLOTYPE;PD
PA165817398;MYELOSUPPRESSION;DISEASE;PA165819278;TPMT*8;HAPLOTYPE;
PA165817398;MYELOSUPPRESSION;DISEASE;PA165819279;TPMT*9;HAPLOTYPE;
PA165817398;MYELOSUPPRESSION;DISEASE;PA165819282;TPMT*12;HAPLOTYPE;
PA165817398;MYELOSUPPRESSION;DISEASE;PA165819295;TPMT*24;HAPLOTYPE;
PA165817398;MYELOSUPPRESSION;DISEASE;PA166131619;NUDT15*1;HAPLOTYPE;
PA165817398;MYELOSUPPRESSION;DISEASE;PA166131620;NUDT15*2;HAPLOTYPE;
PA165817398;MYELOSUPPRESSION;DISEASE;PA166131621;NUDT15*3;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165818765;CYP2B6*7;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165948032;CYP2E1*1A;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165948040;CYP2E1*5B;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165949098;NAT2*4;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165949099;NAT2*16;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165949138;NAT2*1;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165951273;HLA-DQA1*01:01;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165951275;HLA-DQA1*01:02;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165951292;HLA-DQA1*02:01;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165951320;HLA-DRB1*01:01;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165951340;HLA-DRB1*01:02;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165951978;HLA-DRB1*13:02;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165952269;HLA-DRB1*15:01;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165955913;HLA-B*44:03;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165956639;HLA-B*58:02;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165956805;HLA-C*02:10;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165957827;HLA-C*14:03;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165958103;HLA-DQB1*06:02;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165958107;HLA-DQB1*06:04;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165958158;HLA-DQB1*02:01;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165958684;CYP2C8*2;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165958686;CYP2C8*4;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165981634;NAT2*5;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165981635;NAT2*6;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165981636;NAT2*7;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165981640;NAT2*14;HAPLOTYPE;PD
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165987830;HLA-B*57:01;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA165987831;HLA-B*58:01;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA166048678;GSTT1 NULL;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA166123428;HLA-A*33:03;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA166181185;CYP2D6*14;HAPLOTYPE;
PA164925725;TOXIC LIVER DISEASE;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;PD
PA444153;FATIGUE;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;PD
PA444153;FATIGUE;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;PD
PA444153;FATIGUE;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;PD
PA444153;FATIGUE;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;PD
PA444153;FATIGUE;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;PD
PA443309;ALCOHOLISM;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA443309;ALCOHOLISM;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA443309;ALCOHOLISM;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA443309;ALCOHOLISM;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA443309;ALCOHOLISM;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;PD
PA443309;ALCOHOLISM;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA443309;ALCOHOLISM;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA443309;ALCOHOLISM;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;PD
PA443309;ALCOHOLISM;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;PD
PA443309;ALCOHOLISM;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;PD
PA166123046;SMOKING CESSATION;DISEASE;PA165924690;CYP2A6*1;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165924691;CYP2A6*46;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165924719;CYP2A6*2;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165924721;CYP2A6*4;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165924744;CYP2A6*17;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165924749;CYP2A6*20;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165924752;CYP2A6*23;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165924753;CYP2A6*24;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165924755;CYP2A6*25;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165924756;CYP2A6*26;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165924757;CYP2A6*27;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165924758;CYP2A6*28;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165980914;CYP2A6*9;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165980915;CYP2A6*12;HAPLOTYPE;
PA166123046;SMOKING CESSATION;DISEASE;PA165980920;CYP2A6*35;HAPLOTYPE;
PA166160459;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR);DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA166160459;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR);DISEASE;PA165816552;CYP2C9*11;HAPLOTYPE;
PA165108401;ACUTE CORONARY SYNDROME;DISEASE;PA165816522;CYP2C19*6;HAPLOTYPE;PD
PA165108401;ACUTE CORONARY SYNDROME;DISEASE;PA165816524;CYP2C19*8;HAPLOTYPE;PD
PA165108401;ACUTE CORONARY SYNDROME;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;PD
PA165108401;ACUTE CORONARY SYNDROME;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA165108401;ACUTE CORONARY SYNDROME;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA165108401;ACUTE CORONARY SYNDROME;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA165108401;ACUTE CORONARY SYNDROME;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA165108401;ACUTE CORONARY SYNDROME;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA165108401;ACUTE CORONARY SYNDROME;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA165108401;ACUTE CORONARY SYNDROME;DISEASE;PA165980637;CYP2C19*4;HAPLOTYPE;PD
PA165108401;ACUTE CORONARY SYNDROME;DISEASE;PA165980638;CYP2C19*5;HAPLOTYPE;PD
PA444417;HEMORRHAGE;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;PD
PA444417;HEMORRHAGE;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA444417;HEMORRHAGE;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA444417;HEMORRHAGE;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA444417;HEMORRHAGE;DISEASE;PA165816546;CYP2C9*5;HAPLOTYPE;PD
PA444417;HEMORRHAGE;DISEASE;PA165816547;CYP2C9*6;HAPLOTYPE;PD
PA444417;HEMORRHAGE;DISEASE;PA165816552;CYP2C9*11;HAPLOTYPE;PD
PA444417;HEMORRHAGE;DISEASE;PA165860685;CYP4F2*1;HAPLOTYPE;
PA444417;HEMORRHAGE;DISEASE;PA165860687;CYP4F2*3;HAPLOTYPE;
PA444417;HEMORRHAGE;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA444417;HEMORRHAGE;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA444417;HEMORRHAGE;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA445746;STOMATITIS;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA445746;STOMATITIS;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA444327;GRANULOMATOUS DISEASE, CHRONIC;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA444327;GRANULOMATOUS DISEASE, CHRONIC;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA445293;FAMILIAL MEDITERRANEAN FEVER;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA445293;FAMILIAL MEDITERRANEAN FEVER;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA443250;ACQUIRED IMMUNODEFICIENCY SYNDROME;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;PD
PA443250;ACQUIRED IMMUNODEFICIENCY SYNDROME;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;PD
PA443250;ACQUIRED IMMUNODEFICIENCY SYNDROME;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA443250;ACQUIRED IMMUNODEFICIENCY SYNDROME;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA444802;LIVER DISEASES, ALCOHOLIC;DISEASE;PA165948040;CYP2E1*5B;HAPLOTYPE;
PA444802;LIVER DISEASES, ALCOHOLIC;DISEASE;PA165981617;CYP2E1*1;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165951320;HLA-DRB1*01:01;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165951734;HLA-DRB1*09:01;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165951978;HLA-DRB1*13:02;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165952135;HLA-DRB1*14:01;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165952269;HLA-DRB1*15:01;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165952289;HLA-DRB1*15:02;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165952368;HLA-DRB1*16:02;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165952829;HLA-A*02:06;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165953564;HLA-A*24:02;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165954144;HLA-A*33:01;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165954643;HLA-B*13:01;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165954712;HLA-B*14:02;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165954769;HLA-B*15:02;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165955215;HLA-B*35:01;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165955891;HLA-B*44:02;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165955913;HLA-B*44:03;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165956201;HLA-B*51:01;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165956463;HLA-B*55:01;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165956881;HLA-C*03:04;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165957046;HLA-C*04:01;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165957658;HLA-C*08:02;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165958073;HLA-DQB1*05:01;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165958077;HLA-DQB1*05:02;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165958103;HLA-DQB1*06:02;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165958105;HLA-DQB1*06:03;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165958117;HLA-DQB1*06:09;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165958158;HLA-DQB1*02:01;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165958175;HLA-DQB1*03:02;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165987830;HLA-B*57:01;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA165987831;HLA-B*58:01;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA166123425;HLA-C*03:02;HAPLOTYPE;
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA166123426;HLA-C*08:01;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA166123427;HLA-A*02:01;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA166123428;HLA-A*33:03;HAPLOTYPE;PD
PA443936;DRUG HYPERSENSITIVITY;DISEASE;PA166123429;HLA-B*48:01;HAPLOTYPE;PD
PA444685;KIDNEY NEOPLASMS;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA444685;KIDNEY NEOPLASMS;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA444685;KIDNEY NEOPLASMS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA444685;KIDNEY NEOPLASMS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA166123203;INTRAGASTRIC PH;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166123203;INTRAGASTRIC PH;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA166123203;INTRAGASTRIC PH;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA166048714;PREGNANCY;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA166048714;PREGNANCY;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA166048714;PREGNANCY;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA166048714;PREGNANCY;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA166048714;PREGNANCY;DISEASE;PA166115843;UGT1A1*36;HAPLOTYPE;
PA166048714;PREGNANCY;DISEASE;PA166115844;UGT1A1*37;HAPLOTYPE;
PA166048714;PREGNANCY;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;
PA444418;GASTROINTESTINAL HEMORRHAGE;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA444418;GASTROINTESTINAL HEMORRHAGE;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA444418;GASTROINTESTINAL HEMORRHAGE;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165819255;SLCO1B1*5;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165819282;TPMT*12;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA165951292;HLA-DQA1*02:01;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA165951320;HLA-DRB1*01:01;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA165953358;HLA-A*11:01;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165954816;HLA-B*15:27;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165955215;HLA-B*35:01;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165956201;HLA-B*51:01;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165957046;HLA-C*04:01;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165958684;CYP2C8*2;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA165958686;CYP2C8*4;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165981641;SLCO1B1*1;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA166123321;CYP2D6*81;HAPLOTYPE;PD
PA443937;DRUG TOXICITY;DISEASE;PA166123427;HLA-A*02:01;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA166171119;DPYD C.2846A>T;HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA166171120;DPYD C.1129-5923C>G, C.1236G>A (HAPB3);HAPLOTYPE;
PA443937;DRUG TOXICITY;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;PD
PA443297;AGRANULOCYTOSIS;DISEASE;PA165951133;HLA-DPB1*04:01;HAPLOTYPE;
PA443297;AGRANULOCYTOSIS;DISEASE;PA165951282;HLA-DQA1*01:03;HAPLOTYPE;PD
PA443297;AGRANULOCYTOSIS;DISEASE;PA165951320;HLA-DRB1*01:01;HAPLOTYPE;
PA443297;AGRANULOCYTOSIS;DISEASE;PA165951501;HLA-DRB1*04:02;HAPLOTYPE;PD
PA443297;AGRANULOCYTOSIS;DISEASE;PA165951678;HLA-DRB1*08:03;HAPLOTYPE;PD
PA443297;AGRANULOCYTOSIS;DISEASE;PA165952408;HLA-DRB3*02:02;HAPLOTYPE;
PA443297;AGRANULOCYTOSIS;DISEASE;PA165952475;HLA-DRB5*02:02;HAPLOTYPE;
PA443297;AGRANULOCYTOSIS;DISEASE;PA165954547;HLA-B*08:01;HAPLOTYPE;PD
PA443297;AGRANULOCYTOSIS;DISEASE;PA165955118;HLA-B*27:05;HAPLOTYPE;PD
PA443297;AGRANULOCYTOSIS;DISEASE;PA165955500;HLA-B*38:01;HAPLOTYPE;
PA443297;AGRANULOCYTOSIS;DISEASE;PA165955505;HLA-B*38:02;HAPLOTYPE;PD
PA443297;AGRANULOCYTOSIS;DISEASE;PA165955543;HLA-B*39:01;HAPLOTYPE;PD
PA443297;AGRANULOCYTOSIS;DISEASE;PA165956674;HLA-B*59:01;HAPLOTYPE;
PA443297;AGRANULOCYTOSIS;DISEASE;PA165957372;HLA-C*07:01;HAPLOTYPE;
PA443297;AGRANULOCYTOSIS;DISEASE;PA165958077;HLA-DQB1*05:02;HAPLOTYPE;
PA443297;AGRANULOCYTOSIS;DISEASE;PA165958097;HLA-DQB1*06:01;HAPLOTYPE;PD
PA443297;AGRANULOCYTOSIS;DISEASE;PA165958158;HLA-DQB1*02:01;HAPLOTYPE;
PA446459;MYOCARDIAL ISCHEMIA;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA446459;MYOCARDIAL ISCHEMIA;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA446459;MYOCARDIAL ISCHEMIA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA445647;SHOCK, SEPTIC;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA445647;SHOCK, SEPTIC;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA446169;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;PD
PA446169;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;PD
PA443829;CYSTIC FIBROSIS;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA443829;CYSTIC FIBROSIS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA443829;CYSTIC FIBROSIS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819251;SLCO1B1*37;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819255;SLCO1B1*5;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819264;SLCO1B1*14;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819265;SLCO1B1*15;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;PD
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;PD
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;PD
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819271;TPMT*3B;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;PD
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819279;TPMT*9;HAPLOTYPE;PD
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819282;TPMT*12;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819291;TPMT*21;HAPLOTYPE;PD
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819295;TPMT*24;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165819296;TPMT*25;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165947864;SLCO1B1*23;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165947872;SLCO1B1*31;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165952368;HLA-DRB1*16:02;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165981641;SLCO1B1*1;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA165988676;SLCO1B1*20;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA166005223;TPMT*32;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA166005224;TPMT*33;HAPLOTYPE;PD
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA166005225;TPMT*34;HAPLOTYPE;PD
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA166119185;TPMT*37;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA166131619;NUDT15*1;HAPLOTYPE;PD
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA166131620;NUDT15*2;HAPLOTYPE;PD
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA166131621;NUDT15*3;HAPLOTYPE;PD
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA166131622;NUDT15*4;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA166131623;NUDT15*5;HAPLOTYPE;
PA446155;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;DISEASE;PA166151814;NUDT15*6;HAPLOTYPE;
PA166185295;DYSPHORIA;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA166185295;DYSPHORIA;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA166185295;DYSPHORIA;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA166185295;DYSPHORIA;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA166185295;DYSPHORIA;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA166185295;DYSPHORIA;DISEASE;PA166123321;CYP2D6*81;HAPLOTYPE;PD
PA444435;HEPATITIS;DISEASE;PA165952269;HLA-DRB1*15:01;HAPLOTYPE;
PA444435;HEPATITIS;DISEASE;PA165952460;HLA-DRB5*01:01;HAPLOTYPE;
PA444435;HEPATITIS;DISEASE;PA165958103;HLA-DQB1*06:02;HAPLOTYPE;
PA443782;CONSTIPATION;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA443782;CONSTIPATION;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA443782;CONSTIPATION;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA443782;CONSTIPATION;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA443782;CONSTIPATION;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA443750;COLITIS, ULCERATIVE;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA443750;COLITIS, ULCERATIVE;DISEASE;PA165958462;NAT1*4;HAPLOTYPE;
PA443750;COLITIS, ULCERATIVE;DISEASE;PA165958463;NAT1*3;HAPLOTYPE;
PA443750;COLITIS, ULCERATIVE;DISEASE;PA165958465;NAT1*10;HAPLOTYPE;
PA443750;COLITIS, ULCERATIVE;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA443750;COLITIS, ULCERATIVE;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA443750;COLITIS, ULCERATIVE;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA443750;COLITIS, ULCERATIVE;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA443580;BURKITT LYMPHOMA;DISEASE;PA165947827;G6PD A- 202A_376G;HAPLOTYPE;
PA166048851;PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA166048851;PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA447276;THROMBOSIS OF CEREBRAL VEINS;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA447276;THROMBOSIS OF CEREBRAL VEINS;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA447276;THROMBOSIS OF CEREBRAL VEINS;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA445018;CARDIOMYOPATHIES;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA445018;CARDIOMYOPATHIES;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA445018;CARDIOMYOPATHIES;DISEASE;PA165816569;CYP2C9*24;HAPLOTYPE;
PA445018;CARDIOMYOPATHIES;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA445018;CARDIOMYOPATHIES;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA165988484;CYP2D6*21;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA165988487;CYP2D6*35;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA165988488;CYP2D6*36;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA445506;RECURRENCE;DISEASE;PA166181185;CYP2D6*14;HAPLOTYPE;
PA444773;LEUKOPENIA;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;PD
PA444773;LEUKOPENIA;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;PD
PA444773;LEUKOPENIA;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;PD
PA444773;LEUKOPENIA;DISEASE;PA165819271;TPMT*3B;HAPLOTYPE;PD
PA444773;LEUKOPENIA;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;PD
PA444773;LEUKOPENIA;DISEASE;PA165819276;TPMT*6;HAPLOTYPE;PD
PA444773;LEUKOPENIA;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA444773;LEUKOPENIA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA444773;LEUKOPENIA;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA444773;LEUKOPENIA;DISEASE;PA166115865;UGT1A1*27;HAPLOTYPE;
PA444773;LEUKOPENIA;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA444773;LEUKOPENIA;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA444773;LEUKOPENIA;DISEASE;PA166131619;NUDT15*1;HAPLOTYPE;PD
PA444773;LEUKOPENIA;DISEASE;PA166131620;NUDT15*2;HAPLOTYPE;PD
PA444773;LEUKOPENIA;DISEASE;PA166131621;NUDT15*3;HAPLOTYPE;PD
PA444773;LEUKOPENIA;DISEASE;PA166131622;NUDT15*4;HAPLOTYPE;PD
PA444773;LEUKOPENIA;DISEASE;PA166131623;NUDT15*5;HAPLOTYPE;PD
PA444773;LEUKOPENIA;DISEASE;PA166151814;NUDT15*6;HAPLOTYPE;PD
PA166129532;TIME TO THERAPEUTIC INR;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA166129532;TIME TO THERAPEUTIC INR;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA166129532;TIME TO THERAPEUTIC INR;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA166129532;TIME TO THERAPEUTIC INR;DISEASE;PA165860685;CYP4F2*1;HAPLOTYPE;
PA166129532;TIME TO THERAPEUTIC INR;DISEASE;PA165860687;CYP4F2*3;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;PD
PA445062;NEOPLASMS;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;PD
PA445062;NEOPLASMS;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;PD
PA445062;NEOPLASMS;DISEASE;PA165819271;TPMT*3B;HAPLOTYPE;PD
PA445062;NEOPLASMS;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;PD
PA445062;NEOPLASMS;DISEASE;PA165819279;TPMT*9;HAPLOTYPE;PD
PA445062;NEOPLASMS;DISEASE;PA165924690;CYP2A6*1;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165924691;CYP2A6*46;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165924721;CYP2A6*4;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165924731;CYP2A6*7;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165924735;CYP2A6*10;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165924736;CYP2A6*11;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165924748;CYP2A6*19;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165953186;HLA-A*03:01;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165958686;CYP2C8*4;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165980914;CYP2A6*9;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165980916;CYP2A6*18;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;PD
PA445062;NEOPLASMS;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;PD
PA445062;NEOPLASMS;DISEASE;PA166048678;GSTT1 NULL;HAPLOTYPE;PD
PA445062;NEOPLASMS;DISEASE;PA166048679;GSTT1 NON-NULL;HAPLOTYPE;PD
PA445062;NEOPLASMS;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA166115844;UGT1A1*37;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA166115845;UGT1A1*60;HAPLOTYPE;PD
PA445062;NEOPLASMS;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA166121127;G6PD MEDITERRANEAN, DALLAS, PANAMA, SASSARI, CAGLIARI, BIRMINGHAM;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA166123427;HLA-A*02:01;HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA445062;NEOPLASMS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA445062;NEOPLASMS;DISEASE;PA166171120;DPYD C.1129-5923C>G, C.1236G>A (HAPB3);HAPLOTYPE;
PA445062;NEOPLASMS;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;
PA447196;ANXIETY DISORDERS;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA447196;ANXIETY DISORDERS;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;PD
PA447196;ANXIETY DISORDERS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA447196;ANXIETY DISORDERS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA447196;ANXIETY DISORDERS;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;PD
PA447196;ANXIETY DISORDERS;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;PD
PA447196;ANXIETY DISORDERS;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;PD
PA447196;ANXIETY DISORDERS;DISEASE;PA166117146;SLC6A4 L ALLELE-RS25531T;HAPLOTYPE;
PA447196;ANXIETY DISORDERS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA447196;ANXIETY DISORDERS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA445465;PULMONARY EMBOLISM;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA445465;PULMONARY EMBOLISM;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA445975;UNCONSCIOUSNESS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA445975;UNCONSCIOUSNESS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA162263534;OTOTOXICITY;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;PD
PA162263534;OTOTOXICITY;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;PD
PA162263534;OTOTOXICITY;DISEASE;PA165819271;TPMT*3B;HAPLOTYPE;
PA162263534;OTOTOXICITY;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA162263534;OTOTOXICITY;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;PD
PA162263534;OTOTOXICITY;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;PD
PA162263534;OTOTOXICITY;DISEASE;PA166048678;GSTT1 NULL;HAPLOTYPE;PD
PA162263534;OTOTOXICITY;DISEASE;PA166048679;GSTT1 NON-NULL;HAPLOTYPE;PD
PA166123298;OVER-ANTICOAGULATION;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA166123298;OVER-ANTICOAGULATION;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA166123298;OVER-ANTICOAGULATION;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA166123298;OVER-ANTICOAGULATION;DISEASE;PA165816546;CYP2C9*5;HAPLOTYPE;PD
PA166123298;OVER-ANTICOAGULATION;DISEASE;PA165816547;CYP2C9*6;HAPLOTYPE;PD
PA166123298;OVER-ANTICOAGULATION;DISEASE;PA165816552;CYP2C9*11;HAPLOTYPE;PD
PA444997;MUSCULAR DISEASES;DISEASE;PA165951320;HLA-DRB1*01:01;HAPLOTYPE;
PA444997;MUSCULAR DISEASES;DISEASE;PA165951530;HLA-DRB1*04:06;HAPLOTYPE;
PA444997;MUSCULAR DISEASES;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA444997;MUSCULAR DISEASES;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA444987;MULTIPLE SCLEROSIS;DISEASE;PA165951493;HLA-DRB1*04:01;HAPLOTYPE;PD
PA444987;MULTIPLE SCLEROSIS;DISEASE;PA165952269;HLA-DRB1*15:01;HAPLOTYPE;
PA444987;MULTIPLE SCLEROSIS;DISEASE;PA165954745;HLA-B*15:01;HAPLOTYPE;PD
PA443756;COLONIC NEOPLASMS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA443756;COLONIC NEOPLASMS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA166129530;TIME TO ACHIEVE STABLE DOSE;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA166129530;TIME TO ACHIEVE STABLE DOSE;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA166129530;TIME TO ACHIEVE STABLE DOSE;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA443670;CEREBRAL INFARCTION;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA443670;CEREBRAL INFARCTION;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA447216;SCHIZOPHRENIA;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA447216;SCHIZOPHRENIA;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA447216;SCHIZOPHRENIA;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165816583;CYP2D6*17;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165951133;HLA-DPB1*04:01;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165951320;HLA-DRB1*01:01;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165951501;HLA-DRB1*04:02;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165952408;HLA-DRB3*02:02;HAPLOTYPE;PD
PA447216;SCHIZOPHRENIA;DISEASE;PA165952475;HLA-DRB5*02:02;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165955500;HLA-B*38:01;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165956674;HLA-B*59:01;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165957372;HLA-C*07:01;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165958077;HLA-DQB1*05:02;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165958158;HLA-DQB1*02:01;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165971559;CYP2D6*7;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA166117146;SLC6A4 L ALLELE-RS25531T;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA166117147;SLC6A4 L ALLELE-RS25531C;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA166181185;CYP2D6*14;HAPLOTYPE;
PA447216;SCHIZOPHRENIA;DISEASE;PA166363479;CYP1A2*35;HAPLOTYPE;
PA445862;THYROTOXICOSIS;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA445862;THYROTOXICOSIS;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA165819278;TPMT*8;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA165819279;TPMT*9;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA165819282;TPMT*12;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA165819295;TPMT*24;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA166131619;NUDT15*1;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA166131620;NUDT15*2;HAPLOTYPE;
PA444620;INFLAMMATION;DISEASE;PA166131621;NUDT15*3;HAPLOTYPE;
PA446878;COCAINE DEPENDENCE;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;
PA446878;COCAINE DEPENDENCE;DISEASE;PA166117146;SLC6A4 L ALLELE-RS25531T;HAPLOTYPE;
PA446878;COCAINE DEPENDENCE;DISEASE;PA166117147;SLC6A4 L ALLELE-RS25531C;HAPLOTYPE;
PA444445;HEPATITIS C;DISEASE;PA165952609;HLA-A*01:01;HAPLOTYPE;
PA444445;HEPATITIS C;DISEASE;PA165955500;HLA-B*38:01;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA165955891;HLA-B*44:02;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA165956704;HLA-C*01:02;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA165956777;HLA-C*02:02;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA165957046;HLA-C*04:01;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA165957192;HLA-C*05:01;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA165957286;HLA-C*06:02;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA165957372;HLA-C*07:01;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA165957722;HLA-C*12:02;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA165957818;HLA-C*14:02;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA165957859;HLA-C*15:02;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA165957927;HLA-C*16:01;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA165957985;HLA-C*17:01;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA444445;HEPATITIS C;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA444445;HEPATITIS C;DISEASE;PA166123425;HLA-C*03:02;HAPLOTYPE;PD
PA444445;HEPATITIS C;DISEASE;PA166123426;HLA-C*08:01;HAPLOTYPE;PD
PA443464;AUTOIMMUNE DISEASES;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA443464;AUTOIMMUNE DISEASES;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA166159284;TREATMENT INTERRUPTIONS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA166159284;TREATMENT INTERRUPTIONS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA443624;RENAL CELL CARCINOMA;DISEASE;PA165987830;HLA-B*57:01;HAPLOTYPE;
PA443624;RENAL CELL CARCINOMA;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;PD
PA443624;RENAL CELL CARCINOMA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;PD
PA443624;RENAL CELL CARCINOMA;DISEASE;PA166115844;UGT1A1*37;HAPLOTYPE;PD
PA443624;RENAL CELL CARCINOMA;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;PD
PA166128807;BILIARY TRACT NEOPLASMS;DISEASE;PA165924690;CYP2A6*1;HAPLOTYPE;
PA166128807;BILIARY TRACT NEOPLASMS;DISEASE;PA165924721;CYP2A6*4;HAPLOTYPE;
PA166128807;BILIARY TRACT NEOPLASMS;DISEASE;PA165924731;CYP2A6*7;HAPLOTYPE;
PA166128807;BILIARY TRACT NEOPLASMS;DISEASE;PA165924735;CYP2A6*10;HAPLOTYPE;
PA166128807;BILIARY TRACT NEOPLASMS;DISEASE;PA165980914;CYP2A6*9;HAPLOTYPE;
PA166128807;BILIARY TRACT NEOPLASMS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA166128807;BILIARY TRACT NEOPLASMS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA166128807;BILIARY TRACT NEOPLASMS;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA445004;MYASTHENIA GRAVIS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA445004;MYASTHENIA GRAVIS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA445999;URTICARIA;DISEASE;PA165951131;HLA-DPB1*03:01;HAPLOTYPE;
PA445999;URTICARIA;DISEASE;PA165951139;HLA-DPB1*05:01;HAPLOTYPE;
PA445999;URTICARIA;DISEASE;PA165951184;HLA-DPB1*13:01;HAPLOTYPE;
PA445999;URTICARIA;DISEASE;PA165951734;HLA-DRB1*09:01;HAPLOTYPE;
PA445999;URTICARIA;DISEASE;PA165951978;HLA-DRB1*13:02;HAPLOTYPE;
PA445999;URTICARIA;DISEASE;PA165958107;HLA-DQB1*06:04;HAPLOTYPE;
PA445999;URTICARIA;DISEASE;PA165958117;HLA-DQB1*06:09;HAPLOTYPE;
PA445999;URTICARIA;DISEASE;PA165958180;HLA-DQB1*03:03;HAPLOTYPE;
PA445676;SKIN DISEASES;DISEASE;PA165954643;HLA-B*13:01;HAPLOTYPE;
PA443886;DIABETES MELLITUS;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA443886;DIABETES MELLITUS;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA443886;DIABETES MELLITUS;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA443886;DIABETES MELLITUS;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA443886;DIABETES MELLITUS;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;
PA443886;DIABETES MELLITUS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA443886;DIABETES MELLITUS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA443886;DIABETES MELLITUS;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165951340;HLA-DRB1*01:02;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165951348;HLA-DRB1*01:03;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165951511;HLA-DRB1*04:04;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165951669;HLA-DRB1*08:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165951678;HLA-DRB1*08:03;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165951757;HLA-DRB1*10:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165951930;HLA-DRB1*12:02;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165951978;HLA-DRB1*13:02;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165952289;HLA-DRB1*15:02;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165952829;HLA-A*02:06;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165952839;HLA-A*02:07;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165953358;HLA-A*11:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165953507;HLA-A*23:01;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165953564;HLA-A*24:02;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165953622;HLA-A*24:07;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954366;HLA-B*07:02;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954643;HLA-B*13:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954649;HLA-B*13:02;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954745;HLA-B*15:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954769;HLA-B*15:02;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954787;HLA-B*15:11;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954792;HLA-B*15:12;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954793;HLA-B*15:13;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954803;HLA-B*15:18;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954809;HLA-B*15:21;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954811;HLA-B*15:24;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954812;HLA-B*15:25;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954816;HLA-B*15:27;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954823;HLA-B*15:32;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165954826;HLA-B*15:35;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165955030;HLA-B*18:01;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165955274;HLA-B*35:10;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165955500;HLA-B*38:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165955505;HLA-B*38:02;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165955543;HLA-B*39:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165955559;HLA-B*39:05;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165955561;HLA-B*39:06;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165955565;HLA-B*39:09;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165955566;HLA-B*39:10;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165955628;HLA-B*40:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165955651;HLA-B*40:02;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165955913;HLA-B*44:03;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956083;HLA-B*46:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956201;HLA-B*51:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956231;HLA-B*51:02;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956366;HLA-B*52:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956438;HLA-B*54:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956463;HLA-B*55:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956471;HLA-B*55:02;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956528;HLA-B*56:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956532;HLA-B*56:02;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956537;HLA-B*56:06;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956674;HLA-B*59:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956680;HLA-B*67:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956686;HLA-B*78:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956704;HLA-C*01:02;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165956881;HLA-C*03:04;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165957046;HLA-C*04:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165957085;HLA-C*04:03;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165957089;HLA-C*04:06;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165957090;HLA-C*04:07;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165957192;HLA-C*05:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165957217;HLA-C*05:09;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165957286;HLA-C*06:02;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165957428;HLA-C*07:04;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165957457;HLA-C*07:27;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165957818;HLA-C*14:02;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165957827;HLA-C*14:03;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165957859;HLA-C*15:02;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165958003;HLA-C*18:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165958073;HLA-DQB1*05:01;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165958077;HLA-DQB1*05:02;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165958162;HLA-DQB1*02:02;HAPLOTYPE;
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165987830;HLA-B*57:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA165987831;HLA-B*58:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA166123425;HLA-C*03:02;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA166123426;HLA-C*08:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA166123427;HLA-A*02:01;HAPLOTYPE;PD
PA445738;STEVENS-JOHNSON SYNDROME;DISEASE;PA166123428;HLA-A*33:03;HAPLOTYPE;PD
PA443319;ALZHEIMER DISEASE;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA443319;ALZHEIMER DISEASE;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA443319;ALZHEIMER DISEASE;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA443319;ALZHEIMER DISEASE;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA443319;ALZHEIMER DISEASE;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA443319;ALZHEIMER DISEASE;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA444367;HEART DEFECTS, CONGENITAL;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;
PA445601;OSTEOSARCOMA;DISEASE;PA166048678;GSTT1 NULL;HAPLOTYPE;PD
PA445601;OSTEOSARCOMA;DISEASE;PA166048679;GSTT1 NON-NULL;HAPLOTYPE;PD
PA443657;CENTRAL NERVOUS SYSTEM DISEASES;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA443657;CENTRAL NERVOUS SYSTEM DISEASES;DISEASE;PA165818753;CYP2B6*2;HAPLOTYPE;
PA444545;HYPERPROLACTINEMIA;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA444545;HYPERPROLACTINEMIA;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA444545;HYPERPROLACTINEMIA;DISEASE;PA165980637;CYP2C19*4;HAPLOTYPE;
PA444546;HYPERSENSITIVITY;DISEASE;PA165949098;NAT2*4;HAPLOTYPE;PD
PA444546;HYPERSENSITIVITY;DISEASE;PA165949099;NAT2*5A;HAPLOTYPE;PD
PA444546;HYPERSENSITIVITY;DISEASE;PA165951292;HLA-DQA1*02:01;HAPLOTYPE;
PA444546;HYPERSENSITIVITY;DISEASE;PA165951320;HLA-DRB1*01:01;HAPLOTYPE;
PA444546;HYPERSENSITIVITY;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;
PA444546;HYPERSENSITIVITY;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;
PA444546;HYPERSENSITIVITY;DISEASE;PA165957046;HLA-C*04:01;HAPLOTYPE;PD
PA444546;HYPERSENSITIVITY;DISEASE;PA165958162;HLA-DQB1*02:02;HAPLOTYPE;
PA444546;HYPERSENSITIVITY;DISEASE;PA165981634;NAT2*5;HAPLOTYPE;PD
PA444546;HYPERSENSITIVITY;DISEASE;PA165981635;NAT2*6;HAPLOTYPE;PD
PA444546;HYPERSENSITIVITY;DISEASE;PA165981636;NAT2*7;HAPLOTYPE;PD
PA444546;HYPERSENSITIVITY;DISEASE;PA165981640;NAT2*14;HAPLOTYPE;PD
PA444546;HYPERSENSITIVITY;DISEASE;PA166123426;HLA-C*08:01;HAPLOTYPE;
PA444339;HALLUCINATIONS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA444339;HALLUCINATIONS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA166170668;CNS DEPRESSION;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA166170668;CNS DEPRESSION;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA166170668;CNS DEPRESSION;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA166170668;CNS DEPRESSION;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA166170668;CNS DEPRESSION;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA166170668;CNS DEPRESSION;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;PD
PA444903;MELANOMA;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;
PA445146;OLIGURIA;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA445146;OLIGURIA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA443265;ADENOCARCINOMA;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA443265;ADENOCARCINOMA;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA443265;ADENOCARCINOMA;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA443265;ADENOCARCINOMA;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA443265;ADENOCARCINOMA;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA443265;ADENOCARCINOMA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA165374639;SUICIDE;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA165374639;SUICIDE;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA165374639;SUICIDE;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA165374639;SUICIDE;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;
PA446852;HOT FLASHES;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA446852;HOT FLASHES;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA446852;HOT FLASHES;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA446852;HOT FLASHES;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA444822;SYSTEMIC LUPUS ERYTHEMATOSUS;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA444822;SYSTEMIC LUPUS ERYTHEMATOSUS;DISEASE;PA165819291;TPMT*21;HAPLOTYPE;
PA444822;SYSTEMIC LUPUS ERYTHEMATOSUS;DISEASE;PA165819295;TPMT*24;HAPLOTYPE;
PA444822;SYSTEMIC LUPUS ERYTHEMATOSUS;DISEASE;PA165819296;TPMT*25;HAPLOTYPE;
PA444822;SYSTEMIC LUPUS ERYTHEMATOSUS;DISEASE;PA166005223;TPMT*32;HAPLOTYPE;
PA444822;SYSTEMIC LUPUS ERYTHEMATOSUS;DISEASE;PA166005224;TPMT*33;HAPLOTYPE;
PA444822;SYSTEMIC LUPUS ERYTHEMATOSUS;DISEASE;PA166005225;TPMT*34;HAPLOTYPE;
PA444822;SYSTEMIC LUPUS ERYTHEMATOSUS;DISEASE;PA166119185;TPMT*37;HAPLOTYPE;
PA444822;SYSTEMIC LUPUS ERYTHEMATOSUS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA444822;SYSTEMIC LUPUS ERYTHEMATOSUS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA446038;VIRUS DISEASES;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA446038;VIRUS DISEASES;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA166151827;ADVERSE EVENTS;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA166151827;ADVERSE EVENTS;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA166151827;ADVERSE EVENTS;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA166151827;ADVERSE EVENTS;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA166151827;ADVERSE EVENTS;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA166151827;ADVERSE EVENTS;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA166151827;ADVERSE EVENTS;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;PD
PA166151827;ADVERSE EVENTS;DISEASE;PA165949098;NAT2*4;HAPLOTYPE;PD
PA166151827;ADVERSE EVENTS;DISEASE;PA165949099;NAT2*5A;HAPLOTYPE;PD
PA166151827;ADVERSE EVENTS;DISEASE;PA165953358;HLA-A*11:01;HAPLOTYPE;PD
PA166151827;ADVERSE EVENTS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166151827;ADVERSE EVENTS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA166151827;ADVERSE EVENTS;DISEASE;PA165981634;NAT2*5;HAPLOTYPE;PD
PA166151827;ADVERSE EVENTS;DISEASE;PA165981635;NAT2*6;HAPLOTYPE;PD
PA166151827;ADVERSE EVENTS;DISEASE;PA165981636;NAT2*7;HAPLOTYPE;PD
PA166151827;ADVERSE EVENTS;DISEASE;PA165981640;NAT2*14;HAPLOTYPE;PD
PA166151827;ADVERSE EVENTS;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;PD
PA166151827;ADVERSE EVENTS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;PD
PA166151827;ADVERSE EVENTS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;PD
PA166151827;ADVERSE EVENTS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA166151827;ADVERSE EVENTS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA443853;DEMENTIA;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA443853;DEMENTIA;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA443853;DEMENTIA;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA443853;DEMENTIA;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA443853;DEMENTIA;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA443853;DEMENTIA;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA443853;DEMENTIA;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA443853;DEMENTIA;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;
PA443853;DEMENTIA;DISEASE;PA166117146;SLC6A4 L ALLELE-RS25531T;HAPLOTYPE;
PA443853;DEMENTIA;DISEASE;PA166117147;SLC6A4 L ALLELE-RS25531C;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819271;TPMT*3B;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819277;TPMT*7;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819279;TPMT*9;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819280;TPMT*10;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819282;TPMT*12;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819283;TPMT*13;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819286;TPMT*16;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819287;TPMT*17;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819288;TPMT*18;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165819293;TPMT*23;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165958462;NAT1*4;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165958463;NAT1*3;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA165958465;NAT1*10;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA443815;CROHN DISEASE;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA443994;EDEMA;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA443994;EDEMA;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA443994;EDEMA;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA443994;EDEMA;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA443994;EDEMA;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA443994;EDEMA;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA443994;EDEMA;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;
PA443994;EDEMA;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA443994;EDEMA;DISEASE;PA166123321;CYP2D6*81;HAPLOTYPE;PD
PA443430;ARTHRITIS;DISEASE;PA166121127;G6PD MEDITERRANEAN, DALLAS, PANAMA, SASSARI, CAGLIARI, BIRMINGHAM;HAPLOTYPE;
PA166115462;DRY MOUTH;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA166115462;DRY MOUTH;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA445208;PAIN;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA445208;PAIN;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA445208;PAIN;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA445208;PAIN;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA445208;PAIN;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA445208;PAIN;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA445208;PAIN;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA445208;PAIN;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA445208;PAIN;DISEASE;PA165816583;CYP2D6*17;HAPLOTYPE;PD
PA445208;PAIN;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA445208;PAIN;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA445208;PAIN;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA445208;PAIN;DISEASE;PA165971559;CYP2D6*7;HAPLOTYPE;
PA445208;PAIN;DISEASE;PA165971594;CYP2D6*40;HAPLOTYPE;PD
PA445208;PAIN;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;PD
PA445208;PAIN;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;PD
PA445208;PAIN;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA445208;PAIN;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA445208;PAIN;DISEASE;PA166128233;CYP3A5*6;HAPLOTYPE;
PA443335;ANAPHYLAXIS;DISEASE;PA165951763;HLA-DRB1*11:01;HAPLOTYPE;PD
PA444750;LEUKEMIA;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA444750;LEUKEMIA;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;
PA444750;LEUKEMIA;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA444750;LEUKEMIA;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA444750;LEUKEMIA;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA444750;LEUKEMIA;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA447209;MOOD DISORDER;DISEASE;PA165954809;HLA-B*15:21;HAPLOTYPE;
PA447209;MOOD DISORDER;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA447209;MOOD DISORDER;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;
PA447209;MOOD DISORDER;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;PD
PA447209;MOOD DISORDER;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;PD
PA447209;MOOD DISORDER;DISEASE;PA166117146;SLC6A4 L ALLELE-RS25531T;HAPLOTYPE;
PA447209;MOOD DISORDER;DISEASE;PA166117147;SLC6A4 L ALLELE-RS25531C;HAPLOTYPE;
PA446975;NEUROTOXICITY SYNDROMES;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA446975;NEUROTOXICITY SYNDROMES;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA446975;NEUROTOXICITY SYNDROMES;DISEASE;PA166117278;CYP2B6*38;HAPLOTYPE;
PA446975;NEUROTOXICITY SYNDROMES;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA446975;NEUROTOXICITY SYNDROMES;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA444584;HYPOTENSIVE DISORDER;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA444584;HYPOTENSIVE DISORDER;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA444584;HYPOTENSIVE DISORDER;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA444584;HYPOTENSIVE DISORDER;DISEASE;PA165816547;CYP2C9*6;HAPLOTYPE;PD
PA162370415;METABOLIC SYNDROME;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA162370415;METABOLIC SYNDROME;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA165819265;SLCO1B1*15;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA165819271;TPMT*3B;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA165951292;HLA-DQA1*02:01;HAPLOTYPE;PD
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;PD
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA165958462;NAT1*4;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA165958463;NAT1*3;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA165958465;NAT1*10;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA166131619;NUDT15*1;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA166131620;NUDT15*2;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA166131621;NUDT15*3;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA166131622;NUDT15*4;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA166131623;NUDT15*5;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA166151814;NUDT15*6;HAPLOTYPE;
PA446116;INFLAMMATORY BOWEL DISEASES;DISEASE;PA166319541;HLA-DQA1*05;HAPLOTYPE;PD
PA445629;SEIZURES;DISEASE;PA165954769;HLA-B*15:02;HAPLOTYPE;
PA445629;SEIZURES;DISEASE;PA165954803;HLA-B*15:18;HAPLOTYPE;
PA445629;SEIZURES;DISEASE;PA165955628;HLA-B*40:01;HAPLOTYPE;
PA444942;METHEMOGLOBINEMIA;DISEASE;PA165947826;G6PD B (REFERENCE);HAPLOTYPE;PD
PA444942;METHEMOGLOBINEMIA;DISEASE;PA165947827;G6PD A- 202A_376G;HAPLOTYPE;PD
PA444942;METHEMOGLOBINEMIA;DISEASE;PA166121127;G6PD MEDITERRANEAN, DALLAS, PANAMA, SASSARI, CAGLIARI, BIRMINGHAM;HAPLOTYPE;PD
PA444683;KIDNEY FAILURE, ACUTE;DISEASE;PA165947827;G6PD A- 202A_376G;HAPLOTYPE;
PA444411;HEMOLYSIS;DISEASE;PA165947826;G6PD B (REFERENCE);HAPLOTYPE;PD
PA444411;HEMOLYSIS;DISEASE;PA165947827;G6PD A- 202A_376G;HAPLOTYPE;PD
PA444411;HEMOLYSIS;DISEASE;PA165947830;G6PD MEDITERRANEAN HAPLOTYPE;HAPLOTYPE;PD
PA444411;HEMOLYSIS;DISEASE;PA166121127;G6PD MEDITERRANEAN, DALLAS, PANAMA, SASSARI, CAGLIARI, BIRMINGHAM;HAPLOTYPE;PD
PA444411;HEMOLYSIS;DISEASE;PA166121153;G6PD CANTON, TAIWAN-HAKKA, GIFU-LIKE, AGRIGENTO-LIKE;HAPLOTYPE;PD
PA443582;BURNS;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA443582;BURNS;DISEASE;PA165947827;G6PD A- 202A_376G;HAPLOTYPE;
PA443582;BURNS;DISEASE;PA165948317;CYP2D6*9;HAPLOTYPE;
PA443582;BURNS;DISEASE;PA165948318;CYP2D6*29;HAPLOTYPE;
PA443434;ARTHRITIS, RHEUMATOID;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA443434;ARTHRITIS, RHEUMATOID;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA443434;ARTHRITIS, RHEUMATOID;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA443434;ARTHRITIS, RHEUMATOID;DISEASE;PA165951493;HLA-DRB1*04:01;HAPLOTYPE;
PA443434;ARTHRITIS, RHEUMATOID;DISEASE;PA165951674;HLA-DRB1*08:02;HAPLOTYPE;
PA443434;ARTHRITIS, RHEUMATOID;DISEASE;PA165958226;HLA-DQB1*04:02;HAPLOTYPE;
PA443434;ARTHRITIS, RHEUMATOID;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA443434;ARTHRITIS, RHEUMATOID;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA443434;ARTHRITIS, RHEUMATOID;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA443434;ARTHRITIS, RHEUMATOID;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA166048740;HELICOBACTER INFECTIONS;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA166048740;HELICOBACTER INFECTIONS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA166048740;HELICOBACTER INFECTIONS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA166048740;HELICOBACTER INFECTIONS;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA445742;STOMACH NEOPLASMS;DISEASE;PA165924690;CYP2A6*1;HAPLOTYPE;
PA445742;STOMACH NEOPLASMS;DISEASE;PA165924721;CYP2A6*4;HAPLOTYPE;
PA445742;STOMACH NEOPLASMS;DISEASE;PA165924731;CYP2A6*7;HAPLOTYPE;
PA445742;STOMACH NEOPLASMS;DISEASE;PA165924735;CYP2A6*10;HAPLOTYPE;
PA445742;STOMACH NEOPLASMS;DISEASE;PA165924736;CYP2A6*11;HAPLOTYPE;
PA445742;STOMACH NEOPLASMS;DISEASE;PA165980914;CYP2A6*9;HAPLOTYPE;
PA445742;STOMACH NEOPLASMS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA445742;STOMACH NEOPLASMS;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA445742;STOMACH NEOPLASMS;DISEASE;PA166117636;UGT1A7*1A;HAPLOTYPE;
PA445742;STOMACH NEOPLASMS;DISEASE;PA166117638;UGT1A7*2;HAPLOTYPE;
PA445742;STOMACH NEOPLASMS;DISEASE;PA166117639;UGT1A7*3;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165951340;HLA-DRB1*01:02;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165951348;HLA-DRB1*01:03;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165951511;HLA-DRB1*04:04;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165951669;HLA-DRB1*08:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165951678;HLA-DRB1*08:03;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165951757;HLA-DRB1*10:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165951930;HLA-DRB1*12:02;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165951978;HLA-DRB1*13:02;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165952289;HLA-DRB1*15:02;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165952829;HLA-A*02:06;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165952839;HLA-A*02:07;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165953358;HLA-A*11:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165953564;HLA-A*24:02;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165953622;HLA-A*24:07;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954643;HLA-B*13:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954649;HLA-B*13:02;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954745;HLA-B*15:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954769;HLA-B*15:02;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954787;HLA-B*15:11;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954792;HLA-B*15:12;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954793;HLA-B*15:13;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954809;HLA-B*15:21;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954811;HLA-B*15:24;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954812;HLA-B*15:25;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954816;HLA-B*15:27;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954823;HLA-B*15:32;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165954826;HLA-B*15:35;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165955030;HLA-B*18:01;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165955274;HLA-B*35:10;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165955500;HLA-B*38:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165955505;HLA-B*38:02;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165955543;HLA-B*39:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165955559;HLA-B*39:05;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165955561;HLA-B*39:06;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165955565;HLA-B*39:09;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165955566;HLA-B*39:10;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165955628;HLA-B*40:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165955913;HLA-B*44:03;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956083;HLA-B*46:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956201;HLA-B*51:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956231;HLA-B*51:02;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956366;HLA-B*52:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956438;HLA-B*54:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956463;HLA-B*55:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956471;HLA-B*55:02;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956528;HLA-B*56:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956532;HLA-B*56:02;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956537;HLA-B*56:06;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956674;HLA-B*59:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956680;HLA-B*67:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956686;HLA-B*78:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165956704;HLA-C*01:02;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165957046;HLA-C*04:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165957085;HLA-C*04:03;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165957089;HLA-C*04:06;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165957090;HLA-C*04:07;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165957192;HLA-C*05:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165957217;HLA-C*05:09;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165957286;HLA-C*06:02;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165957457;HLA-C*07:27;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165957818;HLA-C*14:02;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165957827;HLA-C*14:03;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165957859;HLA-C*15:02;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165958003;HLA-C*18:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165958073;HLA-DQB1*05:01;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165958077;HLA-DQB1*05:02;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165958162;HLA-DQB1*02:02;HAPLOTYPE;
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165987830;HLA-B*57:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA165987831;HLA-B*58:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA166123425;HLA-C*03:02;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA166123426;HLA-C*08:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA166123427;HLA-A*02:01;HAPLOTYPE;PD
PA444059;EPIDERMAL NECROLYSIS, TOXIC;DISEASE;PA166123428;HLA-A*33:03;HAPLOTYPE;
PA444528;HYPERLIPIDEMIAS;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;PD
PA444528;HYPERLIPIDEMIAS;DISEASE;PA165819222;CYP3A4*4;HAPLOTYPE;PD
PA444528;HYPERLIPIDEMIAS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA444570;HYPOGLYCEMIA;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA444570;HYPOGLYCEMIA;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA444570;HYPOGLYCEMIA;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA165108357;ERYTHEMA MULTIFORME NOS;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;
PA445683;SKIN NEOPLASMS;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA445683;SKIN NEOPLASMS;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA445683;SKIN NEOPLASMS;DISEASE;PA165819271;TPMT*3B;HAPLOTYPE;
PA445683;SKIN NEOPLASMS;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA166248341;PRIMARY GRAFT FAILURE;DISEASE;PA166131619;NUDT15*1;HAPLOTYPE;
PA166248341;PRIMARY GRAFT FAILURE;DISEASE;PA166131620;NUDT15*2;HAPLOTYPE;
PA166248341;PRIMARY GRAFT FAILURE;DISEASE;PA166131621;NUDT15*3;HAPLOTYPE;
PA166248341;PRIMARY GRAFT FAILURE;DISEASE;PA166131622;NUDT15*4;HAPLOTYPE;
PA166248341;PRIMARY GRAFT FAILURE;DISEASE;PA166131623;NUDT15*5;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165924690;CYP2A6*1;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165924721;CYP2A6*4;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165924731;CYP2A6*7;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165924735;CYP2A6*10;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165980914;CYP2A6*9;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA165988487;CYP2D6*35;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA166123207;OVERALL SURVIVAL;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA444648;JAUNDICE;DISEASE;PA165952269;HLA-DRB1*15:01;HAPLOTYPE;
PA444648;JAUNDICE;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA444648;JAUNDICE;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA444648;JAUNDICE;DISEASE;PA166115843;UGT1A1*36;HAPLOTYPE;
PA444281;GLAUCOMA;DISEASE;PA165956674;HLA-B*59:01;HAPLOTYPE;
PA165111675;DRUG RESISTANCE;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA165111675;DRUG RESISTANCE;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA166048850;SOFT TISSUE NEOPLASMS;DISEASE;PA165987830;HLA-B*57:01;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA444109;EXANTHEMA;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA444109;EXANTHEMA;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA444109;EXANTHEMA;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA444109;EXANTHEMA;DISEASE;PA165951320;HLA-DRB1*01:01;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA165951504;HLA-DRB1*04:03;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA165953186;HLA-A*03:01;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA165953825;HLA-A*26:01;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA165954745;HLA-B*15:01;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA165954769;HLA-B*15:02;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA165955262;HLA-B*35:05;HAPLOTYPE;PD
PA444109;EXANTHEMA;DISEASE;PA165957046;HLA-C*04:01;HAPLOTYPE;PD
PA444109;EXANTHEMA;DISEASE;PA165957658;HLA-C*08:02;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA166123425;HLA-C*03:02;HAPLOTYPE;PD
PA444109;EXANTHEMA;DISEASE;PA166123427;HLA-A*02:01;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA166123429;HLA-B*48:01;HAPLOTYPE;
PA444109;EXANTHEMA;DISEASE;PA166181184;CYP2D6*114;HAPLOTYPE;
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA165924690;CYP2A6*1;HAPLOTYPE;
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA165924721;CYP2A6*4;HAPLOTYPE;
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA165924731;CYP2A6*7;HAPLOTYPE;
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA165980914;CYP2A6*9;HAPLOTYPE;
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA166115844;UGT1A1*37;HAPLOTYPE;
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA166115845;UGT1A1*60;HAPLOTYPE;
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA166117621;UGT1A6*2A;HAPLOTYPE;PD
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA166117639;UGT1A7*3;HAPLOTYPE;PD
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA166121127;G6PD MEDITERRANEAN, DALLAS, PANAMA, SASSARI, CAGLIARI, BIRMINGHAM;HAPLOTYPE;
PA446108;COLORECTAL NEOPLASMS;DISEASE;PA166171119;DPYD C.2846A>T;HAPLOTYPE;
PA443890;DIABETES MELLITUS, TYPE 2;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA443890;DIABETES MELLITUS, TYPE 2;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA443890;DIABETES MELLITUS, TYPE 2;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA443890;DIABETES MELLITUS, TYPE 2;DISEASE;PA165947827;G6PD A- 202A_376G;HAPLOTYPE;
PA443890;DIABETES MELLITUS, TYPE 2;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;
PA443890;DIABETES MELLITUS, TYPE 2;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA443890;DIABETES MELLITUS, TYPE 2;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA443890;DIABETES MELLITUS, TYPE 2;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA443890;DIABETES MELLITUS, TYPE 2;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;
PA444807;LONG QT SYNDROME;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA444807;LONG QT SYNDROME;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165818807;CYP2B6*9;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165819255;SLCO1B1*5;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165819278;TPMT*8;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165819279;TPMT*9;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165819282;TPMT*12;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165819295;TPMT*24;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165981641;SLCO1B1*1;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;PD
PA166123507;DISCONTINUATION;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;PD
PA166123507;DISCONTINUATION;DISEASE;PA166131619;NUDT15*1;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA166131620;NUDT15*2;HAPLOTYPE;
PA166123507;DISCONTINUATION;DISEASE;PA166131621;NUDT15*3;HAPLOTYPE;
PA162263533;NEPHROTOXICITY;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA162263533;NEPHROTOXICITY;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA133888799;ORGAN TRANSPLANTATION;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;PD
PA133888799;ORGAN TRANSPLANTATION;DISEASE;PA165819221;CYP3A4*3;HAPLOTYPE;PD
PA133888799;ORGAN TRANSPLANTATION;DISEASE;PA165819244;CYP3A4*20;HAPLOTYPE;PD
PA133888799;ORGAN TRANSPLANTATION;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;PD
PA133888799;ORGAN TRANSPLANTATION;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA133888799;ORGAN TRANSPLANTATION;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA443472;BACK PAIN;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA166129562;TIME BELOW THERAPEUTIC RANGE;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA166129562;TIME BELOW THERAPEUTIC RANGE;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA166129562;TIME BELOW THERAPEUTIC RANGE;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA443678;CEREBROVASCULAR DISORDERS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA443678;CEREBROVASCULAR DISORDERS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA166128371;PLATELET AGGREGATION INHIBITION;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA166128371;PLATELET AGGREGATION INHIBITION;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA166128371;PLATELET AGGREGATION INHIBITION;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166128371;PLATELET AGGREGATION INHIBITION;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA447240;PEPTIC ULCER;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA447240;PEPTIC ULCER;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA447240;PEPTIC ULCER;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA447240;PEPTIC ULCER;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA445526;RESPIRATORY TRACT INFECTIONS;DISEASE;PA165816524;CYP2C19*8;HAPLOTYPE;
PA445526;RESPIRATORY TRACT INFECTIONS;DISEASE;PA165816525;CYP2C19*9;HAPLOTYPE;
PA445526;RESPIRATORY TRACT INFECTIONS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA445526;RESPIRATORY TRACT INFECTIONS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA445526;RESPIRATORY TRACT INFECTIONS;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA444682;KIDNEY DISEASES;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA444682;KIDNEY DISEASES;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA444682;KIDNEY DISEASES;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA444682;KIDNEY DISEASES;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;
PA444682;KIDNEY DISEASES;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;
PA166129531;TIME IN THERAPEUTIC RANGE;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA166129531;TIME IN THERAPEUTIC RANGE;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA166129531;TIME IN THERAPEUTIC RANGE;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA153619833;PERIPHERAL VASCULAR DISEASES;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA153619833;PERIPHERAL VASCULAR DISEASES;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA444395;HEMATOLOGIC DISORDER;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA444395;HEMATOLOGIC DISORDER;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA444395;HEMATOLOGIC DISORDER;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA444395;HEMATOLOGIC DISORDER;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA444395;HEMATOLOGIC DISORDER;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA444395;HEMATOLOGIC DISORDER;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA444614;INFECTIOUS DISEASE;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA444614;INFECTIOUS DISEASE;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA444614;INFECTIOUS DISEASE;DISEASE;PA165952269;HLA-DRB1*15:01;HAPLOTYPE;
PA444614;INFECTIOUS DISEASE;DISEASE;PA165952460;HLA-DRB5*01:01;HAPLOTYPE;
PA444614;INFECTIOUS DISEASE;DISEASE;PA165958103;HLA-DQB1*06:02;HAPLOTYPE;
PA444614;INFECTIOUS DISEASE;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA444614;INFECTIOUS DISEASE;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA443548;BRADYCARDIA;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA443548;BRADYCARDIA;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA166123766;PLATELET AGGREGATION;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA166123766;PLATELET AGGREGATION;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA166123766;PLATELET AGGREGATION;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA166123766;PLATELET AGGREGATION;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166123766;PLATELET AGGREGATION;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA445619;SCOLIOSIS;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA445619;SCOLIOSIS;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA445619;SCOLIOSIS;DISEASE;PA165818765;CYP2B6*7;HAPLOTYPE;
PA445619;SCOLIOSIS;DISEASE;PA165818807;CYP2B6*9;HAPLOTYPE;
PA445619;SCOLIOSIS;DISEASE;PA165818808;CYP2B6*18;HAPLOTYPE;
PA445220;PANCREATITIS;DISEASE;PA165951292;HLA-DQA1*02:01;HAPLOTYPE;PD
PA445220;PANCREATITIS;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;PD
PA446171;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;DISEASE;PA166048678;GSTT1 NULL;HAPLOTYPE;PD
PA446171;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;DISEASE;PA166048679;GSTT1 NON-NULL;HAPLOTYPE;PD
PA446171;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA446171;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA446171;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA446171;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE;DISEASE;PA166115865;UGT1A1*27;HAPLOTYPE;
PA446956;SEROTONIN SYNDROME;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA446956;SEROTONIN SYNDROME;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA446956;SEROTONIN SYNDROME;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA445846;THROMBOCYTOPENIA;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;PD
PA445846;THROMBOCYTOPENIA;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;PD
PA445846;THROMBOCYTOPENIA;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;PD
PA445846;THROMBOCYTOPENIA;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;PD
PA445846;THROMBOCYTOPENIA;DISEASE;PA165819279;TPMT*9;HAPLOTYPE;PD
PA445846;THROMBOCYTOPENIA;DISEASE;PA165819291;TPMT*21;HAPLOTYPE;PD
PA445846;THROMBOCYTOPENIA;DISEASE;PA166005224;TPMT*33;HAPLOTYPE;PD
PA445846;THROMBOCYTOPENIA;DISEASE;PA166005225;TPMT*34;HAPLOTYPE;PD
PA445846;THROMBOCYTOPENIA;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;PD
PA445846;THROMBOCYTOPENIA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;PD
PA445846;THROMBOCYTOPENIA;DISEASE;PA166115845;UGT1A1*60;HAPLOTYPE;
PA447211;OBSESSIVE-COMPULSIVE DISORDER;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;PD
PA447211;OBSESSIVE-COMPULSIVE DISORDER;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA447211;OBSESSIVE-COMPULSIVE DISORDER;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA447211;OBSESSIVE-COMPULSIVE DISORDER;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA447211;OBSESSIVE-COMPULSIVE DISORDER;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA447211;OBSESSIVE-COMPULSIVE DISORDER;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA447211;OBSESSIVE-COMPULSIVE DISORDER;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA447211;OBSESSIVE-COMPULSIVE DISORDER;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA447211;OBSESSIVE-COMPULSIVE DISORDER;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA447211;OBSESSIVE-COMPULSIVE DISORDER;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA447211;OBSESSIVE-COMPULSIVE DISORDER;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;PD
PA447211;OBSESSIVE-COMPULSIVE DISORDER;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;PD
PA447211;OBSESSIVE-COMPULSIVE DISORDER;DISEASE;PA166123321;CYP2D6*81;HAPLOTYPE;PD
PA447268;TARDIVE DYSKINESIA;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA447268;TARDIVE DYSKINESIA;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA447268;TARDIVE DYSKINESIA;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA447268;TARDIVE DYSKINESIA;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA447268;TARDIVE DYSKINESIA;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA447268;TARDIVE DYSKINESIA;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA447268;TARDIVE DYSKINESIA;DISEASE;PA165971559;CYP2D6*7;HAPLOTYPE;
PA447268;TARDIVE DYSKINESIA;DISEASE;PA166181185;CYP2D6*14;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA165924690;CYP2A6*1;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA165924721;CYP2A6*4;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA165924731;CYP2A6*7;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA165924735;CYP2A6*10;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA165980914;CYP2A6*9;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA165988487;CYP2D6*35;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA166048678;GSTT1 NULL;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA166048679;GSTT1 NON-NULL;HAPLOTYPE;
PA166123026;PROGRESSION-FREE SURVIVAL;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA446366;STILL'S DISEASE, ADULT-ONSET;DISEASE;PA165952269;HLA-DRB1*15:01;HAPLOTYPE;
PA445048;NAUSEA;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA445048;NAUSEA;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA445048;NAUSEA;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA445048;NAUSEA;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA445048;NAUSEA;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA445048;NAUSEA;DISEASE;PA165819265;SLCO1B1*15;HAPLOTYPE;
PA445048;NAUSEA;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA445048;NAUSEA;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA445048;NAUSEA;DISEASE;PA166123321;CYP2D6*81;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165816552;CYP2C9*11;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA165818770;CYP2B6*11;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165948032;CYP2E1*1A;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA165948040;CYP2E1*5B;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA165949098;NAT2*4;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA165949099;NAT2*5A;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA165949124;NAT2*6J;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165949129;NAT2*6O;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165949138;NAT2*12A;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA165951275;HLA-DQA1*01:02;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165956366;HLA-B*52:01;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165957046;HLA-C*04:01;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165958073;HLA-DQB1*05:01;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165958077;HLA-DQB1*05:02;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165958080;HLA-DQB1*05:03;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165958158;HLA-DQB1*02:01;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA165981634;NAT2*5;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA165981635;NAT2*6;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA165981636;NAT2*7;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA165981640;NAT2*14;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA166048678;GSTT1 NULL;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA166048679;GSTT1 NON-NULL;HAPLOTYPE;PD
PA445941;TUBERCULOSIS;DISEASE;PA166115839;NAT2*7G;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA166115843;UGT1A1*36;HAPLOTYPE;
PA445941;TUBERCULOSIS;DISEASE;PA166115844;UGT1A1*37;HAPLOTYPE;
PA446879;ALCOHOL-RELATED DISORDERS;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA446879;ALCOHOL-RELATED DISORDERS;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA446879;ALCOHOL-RELATED DISORDERS;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA446879;ALCOHOL-RELATED DISORDERS;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA446879;ALCOHOL-RELATED DISORDERS;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA446879;ALCOHOL-RELATED DISORDERS;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA446879;ALCOHOL-RELATED DISORDERS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA446879;ALCOHOL-RELATED DISORDERS;DISEASE;PA166123321;CYP2D6*81;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165951504;HLA-DRB1*04:03;HAPLOTYPE;
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165952142;HLA-DRB1*14:05;HAPLOTYPE;
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165952609;HLA-A*01:01;HAPLOTYPE;
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165952839;HLA-A*02:07;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165953964;HLA-A*30:01;HAPLOTYPE;
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165954643;HLA-B*13:01;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165954649;HLA-B*13:02;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165954745;HLA-B*15:01;HAPLOTYPE;
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165954769;HLA-B*15:02;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165954787;HLA-B*15:11;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165954807;HLA-B*15:19;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165954816;HLA-B*15:27;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165955138;HLA-B*27:09;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165955215;HLA-B*35:01;HAPLOTYPE;
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165955505;HLA-B*38:02;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165955651;HLA-B*40:02;HAPLOTYPE;
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165955913;HLA-B*44:03;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165956139;HLA-B*48:04;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA165987831;HLA-B*58:01;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA166123426;HLA-C*08:01;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA166123427;HLA-A*02:01;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA166123428;HLA-A*33:03;HAPLOTYPE;PD
PA162316739;MACULOPAPULAR EXANTHEMA;DISEASE;PA166123430;HLA-DRB1*03:01;HAPLOTYPE;PD
PA445058;METASTATIC NEOPLASM;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA445058;METASTATIC NEOPLASM;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA445058;METASTATIC NEOPLASM;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;
PA447218;PHYSIOLOGICAL SEXUAL DISORDER;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;
PA447218;PHYSIOLOGICAL SEXUAL DISORDER;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;
PA166123306;AGITATION;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA166123306;AGITATION;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA166123306;AGITATION;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA166123306;AGITATION;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA166123306;AGITATION;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA166123306;AGITATION;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA166123306;AGITATION;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA166123306;AGITATION;DISEASE;PA166123321;CYP2D6*81;HAPLOTYPE;PD
PA444352;HEAD AND NECK NEOPLASMS;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA444352;HEAD AND NECK NEOPLASMS;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA444352;HEAD AND NECK NEOPLASMS;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA444352;HEAD AND NECK NEOPLASMS;DISEASE;PA165819271;TPMT*3B;HAPLOTYPE;
PA444352;HEAD AND NECK NEOPLASMS;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA444352;HEAD AND NECK NEOPLASMS;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165819265;SLCO1B1*15;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165949098;NAT2*4;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165949099;NAT2*5A;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165949138;NAT2*12A;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165951121;HLA-DPB1*01:01;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165951154;HLA-DPB1*10:01;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165951292;HLA-DQA1*02:01;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165951511;HLA-DRB1*04:04;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165952269;HLA-DRB1*15:01;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165952297;HLA-DRB1*15:03;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165952366;HLA-DRB1*16:01;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165952609;HLA-A*01:01;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165953969;HLA-A*30:02;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165954144;HLA-A*33:01;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165954547;HLA-B*08:01;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165955030;HLA-B*18:01;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165955543;HLA-B*39:01;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165956366;HLA-B*52:01;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165956579;HLA-B*57:03;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165957286;HLA-C*06:02;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165957729;HLA-C*12:03;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165958073;HLA-DQB1*05:01;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165958077;HLA-DQB1*05:02;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165958080;HLA-DQB1*05:03;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165958103;HLA-DQB1*06:02;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165958158;HLA-DQB1*02:01;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165958180;HLA-DQB1*03:03;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165981634;NAT2*5;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165981635;NAT2*6;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165981636;NAT2*7;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165981640;NAT2*14;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165981641;SLCO1B1*1;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165987830;HLA-B*57:01;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA165987831;HLA-B*58:01;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA166123425;HLA-C*03:02;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA166123430;HLA-DRB1*03:01;HAPLOTYPE;PD
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA166119041;DRUG-INDUCED LIVER INJURY;DISEASE;PA166288241;HLA-B*35:02;HAPLOTYPE;PD
PA166114454;TRANSPLANT REJECTION;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA166114454;TRANSPLANT REJECTION;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA166114454;TRANSPLANT REJECTION;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;
PA166114454;TRANSPLANT REJECTION;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA166114454;TRANSPLANT REJECTION;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA166114454;TRANSPLANT REJECTION;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA166114454;TRANSPLANT REJECTION;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA166114454;TRANSPLANT REJECTION;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA166114454;TRANSPLANT REJECTION;DISEASE;PA166128233;CYP3A5*6;HAPLOTYPE;
PA166114454;TRANSPLANT REJECTION;DISEASE;PA166128234;CYP3A5*7;HAPLOTYPE;
PA444511;HYPERBILIRUBINEMIA;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;PD
PA444511;HYPERBILIRUBINEMIA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;PD
PA444511;HYPERBILIRUBINEMIA;DISEASE;PA166115843;UGT1A1*36;HAPLOTYPE;PD
PA444511;HYPERBILIRUBINEMIA;DISEASE;PA166115844;UGT1A1*37;HAPLOTYPE;PD
PA444511;HYPERBILIRUBINEMIA;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;PD
PA444511;HYPERBILIRUBINEMIA;DISEASE;PA166115865;UGT1A1*27;HAPLOTYPE;PD
PA443840;DEAFNESS;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;PD
PA443840;DEAFNESS;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;PD
PA443840;DEAFNESS;DISEASE;PA166048678;GSTT1 NULL;HAPLOTYPE;PD
PA443840;DEAFNESS;DISEASE;PA166048679;GSTT1 NON-NULL;HAPLOTYPE;PD
PA445009;MYCOSES;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA445009;MYCOSES;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA445009;MYCOSES;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA445009;MYCOSES;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA443965;DYSPEPSIA;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA443965;DYSPEPSIA;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA443796;CORONARY ARTERY DISEASE;DISEASE;PA165816524;CYP2C19*8;HAPLOTYPE;
PA443796;CORONARY ARTERY DISEASE;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;PD
PA443796;CORONARY ARTERY DISEASE;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA443796;CORONARY ARTERY DISEASE;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA443796;CORONARY ARTERY DISEASE;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA443796;CORONARY ARTERY DISEASE;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA443796;CORONARY ARTERY DISEASE;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA443796;CORONARY ARTERY DISEASE;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA443796;CORONARY ARTERY DISEASE;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA443796;CORONARY ARTERY DISEASE;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165980637;CYP2C19*4;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA166123321;CYP2D6*81;HAPLOTYPE;PD
PA447207;DEPRESSIVE DISORDER;DISEASE;PA166181185;CYP2D6*14;HAPLOTYPE;
PA446336;SEVERE COMBINED IMMUNODEFICIENCY;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA444178;FEVER;DISEASE;PA165951644;HLA-DRB1*07:01;HAPLOTYPE;
PA445594;SARCOMA;DISEASE;PA165987830;HLA-B*57:01;HAPLOTYPE;
PA444797;LIVER CIRRHOSIS;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA443928;DIZZINESS;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA443928;DIZZINESS;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA443928;DIZZINESS;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA443928;DIZZINESS;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA443928;DIZZINESS;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA443928;DIZZINESS;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;
PA443928;DIZZINESS;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;
PA444104;ESOPHAGITIS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA444104;ESOPHAGITIS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA444104;ESOPHAGITIS;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA447194;AGORAPHOBIA;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA447194;AGORAPHOBIA;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA128406954;WEIGHT GAIN;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA128406954;WEIGHT GAIN;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA128406954;WEIGHT GAIN;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA128406954;WEIGHT GAIN;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA128406954;WEIGHT GAIN;DISEASE;PA165958685;CYP2C8*3;HAPLOTYPE;
PA128406954;WEIGHT GAIN;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;
PA128406954;WEIGHT GAIN;DISEASE;PA166242948;CYP2C8*1;HAPLOTYPE;
PA443340;ANEMIA;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;
PA443340;ANEMIA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;
PA445522;RESPIRATORY INSUFFICIENCY;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA445522;RESPIRATORY INSUFFICIENCY;DISEASE;PA165954366;HLA-B*07:02;HAPLOTYPE;PD
PA445522;RESPIRATORY INSUFFICIENCY;DISEASE;PA165957396;HLA-C*07:02;HAPLOTYPE;PD
PA445522;RESPIRATORY INSUFFICIENCY;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA446863;HEPATITIS C, CHRONIC;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;PD
PA446863;HEPATITIS C, CHRONIC;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;PD
PA445371;POISONING;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA445371;POISONING;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA446713;NEUROENDOCRINE TUMORS;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA446713;NEUROENDOCRINE TUMORS;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA446713;NEUROENDOCRINE TUMORS;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA446713;NEUROENDOCRINE TUMORS;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA443940;PATENT DUCTUS ARTERIOSUS;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165816583;CYP2D6*17;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165948317;CYP2D6*9;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA447208;MENTAL DISORDERS;DISEASE;PA165988480;CYP2D6*2XN;HAPLOTYPE;
PA445096;NEURALGIA;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;
PA446432;BETA-THALASSEMIA AND RELATED DISEASES;DISEASE;PA166117614;UGT1A6*1A;HAPLOTYPE;
PA446432;BETA-THALASSEMIA AND RELATED DISEASES;DISEASE;PA166117621;UGT1A6*2A;HAPLOTYPE;
PA445089;NEPHROTIC SYNDROME;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA445089;NEPHROTIC SYNDROME;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA445973;ULCER;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA445973;ULCER;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA445973;ULCER;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA165108929;BINGE EATING DISORDER;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA165108929;BINGE EATING DISORDER;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA165108929;BINGE EATING DISORDER;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA166128095;TREATMENT FAILURE;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA166128095;TREATMENT FAILURE;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166128095;TREATMENT FAILURE;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA166128095;TREATMENT FAILURE;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA166128095;TREATMENT FAILURE;DISEASE;PA165980637;CYP2C19*4;HAPLOTYPE;
PA166114458;HEART TRANSPLANTATION;DISEASE;PA165819268;TPMT*1;HAPLOTYPE;
PA166114458;HEART TRANSPLANTATION;DISEASE;PA165819269;TPMT*2;HAPLOTYPE;
PA166114458;HEART TRANSPLANTATION;DISEASE;PA165819270;TPMT*3A;HAPLOTYPE;
PA166114458;HEART TRANSPLANTATION;DISEASE;PA165819272;TPMT*3C;HAPLOTYPE;
PA166114458;HEART TRANSPLANTATION;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA166114458;HEART TRANSPLANTATION;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA166114458;HEART TRANSPLANTATION;DISEASE;PA166128233;CYP3A5*6;HAPLOTYPE;PD
PA166114458;HEART TRANSPLANTATION;DISEASE;PA166128234;CYP3A5*7;HAPLOTYPE;PD
PA447199;BIPOLAR DISORDER;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA447199;BIPOLAR DISORDER;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA447199;BIPOLAR DISORDER;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA447199;BIPOLAR DISORDER;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA447199;BIPOLAR DISORDER;DISEASE;PA165954030;HLA-A*31:01;HAPLOTYPE;
PA447199;BIPOLAR DISORDER;DISEASE;PA165954769;HLA-B*15:02;HAPLOTYPE;
PA447199;BIPOLAR DISORDER;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA447199;BIPOLAR DISORDER;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA447278;DEPRESSION;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA447278;DEPRESSION;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA447278;DEPRESSION;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA447278;DEPRESSION;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA447278;DEPRESSION;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA447278;DEPRESSION;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA447278;DEPRESSION;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA447278;DEPRESSION;DISEASE;PA165818750;CYP2B6*1;HAPLOTYPE;PD
PA447278;DEPRESSION;DISEASE;PA165818757;CYP2B6*4;HAPLOTYPE;PD
PA447278;DEPRESSION;DISEASE;PA165818760;CYP2B6*5;HAPLOTYPE;PD
PA447278;DEPRESSION;DISEASE;PA165818762;CYP2B6*6;HAPLOTYPE;PD
PA447278;DEPRESSION;DISEASE;PA165818765;CYP2B6*7;HAPLOTYPE;PD
PA447278;DEPRESSION;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA447278;DEPRESSION;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA447278;DEPRESSION;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA447278;DEPRESSION;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;
PA447278;DEPRESSION;DISEASE;PA166116465;SLC6A4 HTTLPR LONG FORM (L ALLELE);HAPLOTYPE;PD
PA447278;DEPRESSION;DISEASE;PA166116466;SLC6A4 HTTLPR SHORT FORM (S ALLELE);HAPLOTYPE;PD
PA447278;DEPRESSION;DISEASE;PA166117146;SLC6A4 L ALLELE-RS25531T;HAPLOTYPE;
PA447278;DEPRESSION;DISEASE;PA166123321;CYP2D6*81;HAPLOTYPE;PD
PA447278;DEPRESSION;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA447278;DEPRESSION;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA446114;ARTHRITIS, GOUTY;DISEASE;PA165987831;HLA-B*58:01;HAPLOTYPE;
PA166124406;PLATELET REACTIVITY;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA166124406;PLATELET REACTIVITY;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166124406;PLATELET REACTIVITY;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA166124406;PLATELET REACTIVITY;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA445431;PROTEINURIA;DISEASE;PA165951674;HLA-DRB1*08:02;HAPLOTYPE;
PA445431;PROTEINURIA;DISEASE;PA165958226;HLA-DQB1*04:02;HAPLOTYPE;
PA443894;DIABETIC NEUROPATHIES;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA443894;DIABETIC NEUROPATHIES;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA166170367;EXTRAPYRAMIDAL SYMPTOMS;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA166170367;EXTRAPYRAMIDAL SYMPTOMS;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA166170367;EXTRAPYRAMIDAL SYMPTOMS;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA166170367;EXTRAPYRAMIDAL SYMPTOMS;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;
PA166170367;EXTRAPYRAMIDAL SYMPTOMS;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA166170367;EXTRAPYRAMIDAL SYMPTOMS;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA447298;VENOUS THROMBOEMBOLISM;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA447298;VENOUS THROMBOEMBOLISM;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;
PA447298;VENOUS THROMBOEMBOLISM;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA131285571;ASPIRIN-INDUCED ASTHMA;DISEASE;PA165951131;HLA-DPB1*03:01;HAPLOTYPE;
PA131285571;ASPIRIN-INDUCED ASTHMA;DISEASE;PA165951133;HLA-DPB1*04:01;HAPLOTYPE;
PA131285571;ASPIRIN-INDUCED ASTHMA;DISEASE;PA165958175;HLA-DQB1*03:02;HAPLOTYPE;
PA447198;AUTISTIC DISORDER;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA447198;AUTISTIC DISORDER;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;
PA447198;AUTISTIC DISORDER;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA447198;AUTISTIC DISORDER;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA447198;AUTISTIC DISORDER;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;
PA446969;VENOUS THROMBOSIS;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;
PA446969;VENOUS THROMBOSIS;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165816522;CYP2C19*6;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165816524;CYP2C19*8;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165816542;CYP2C9*1;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165816543;CYP2C9*2;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165816544;CYP2C9*3;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165816545;CYP2C9*4;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165816546;CYP2C9*5;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165816547;CYP2C9*6;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165816549;CYP2C9*8;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165816552;CYP2C9*11;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165980637;CYP2C19*4;HAPLOTYPE;PD
PA443635;CARDIOVASCULAR DISEASES;DISEASE;PA165980638;CYP2C19*5;HAPLOTYPE;PD
PA443636;CAROTID ARTERY DISEASES;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA443636;CAROTID ARTERY DISEASES;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA443622;CARCINOMA, NON-SMALL-CELL LUNG;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA443622;CARCINOMA, NON-SMALL-CELL LUNG;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;PD
PA443622;CARCINOMA, NON-SMALL-CELL LUNG;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA443622;CARCINOMA, NON-SMALL-CELL LUNG;DISEASE;PA165924690;CYP2A6*1;HAPLOTYPE;
PA443622;CARCINOMA, NON-SMALL-CELL LUNG;DISEASE;PA165924721;CYP2A6*4;HAPLOTYPE;
PA443622;CARCINOMA, NON-SMALL-CELL LUNG;DISEASE;PA165924731;CYP2A6*7;HAPLOTYPE;
PA443622;CARCINOMA, NON-SMALL-CELL LUNG;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA443622;CARCINOMA, NON-SMALL-CELL LUNG;DISEASE;PA165980914;CYP2A6*9;HAPLOTYPE;
PA443622;CARCINOMA, NON-SMALL-CELL LUNG;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA443622;CARCINOMA, NON-SMALL-CELL LUNG;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA443622;CARCINOMA, NON-SMALL-CELL LUNG;DISEASE;PA166181184;CYP2D6*114;HAPLOTYPE;
PA443622;CARCINOMA, NON-SMALL-CELL LUNG;DISEASE;PA166181185;CYP2D6*14;HAPLOTYPE;
PA443970;DYSTONIA;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;
PA443970;DYSTONIA;DISEASE;PA165816578;CYP2D6*3;HAPLOTYPE;PD
PA443970;DYSTONIA;DISEASE;PA165816579;CYP2D6*4;HAPLOTYPE;PD
PA443970;DYSTONIA;DISEASE;PA165816581;CYP2D6*6;HAPLOTYPE;PD
PA443970;DYSTONIA;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;PD
PA443970;DYSTONIA;DISEASE;PA165816584;CYP2D6*41;HAPLOTYPE;
PA443970;DYSTONIA;DISEASE;PA165948092;CYP2D6*5;HAPLOTYPE;PD
PA443970;DYSTONIA;DISEASE;PA165971559;CYP2D6*7;HAPLOTYPE;PD
PA443970;DYSTONIA;DISEASE;PA166181185;CYP2D6*14;HAPLOTYPE;PD
PA443899;DIARRHEA;DISEASE;PA166115841;UGT1A1*1;HAPLOTYPE;PD
PA443899;DIARRHEA;DISEASE;PA166115842;UGT1A1*28;HAPLOTYPE;PD
PA443899;DIARRHEA;DISEASE;PA166115844;UGT1A1*37;HAPLOTYPE;
PA443899;DIARRHEA;DISEASE;PA166115858;UGT1A1*6;HAPLOTYPE;PD
PA443899;DIARRHEA;DISEASE;PA166117636;UGT1A7*1A;HAPLOTYPE;
PA443899;DIARRHEA;DISEASE;PA166117638;UGT1A7*2;HAPLOTYPE;
PA443899;DIARRHEA;DISEASE;PA166117639;UGT1A7*3;HAPLOTYPE;
PA443899;DIARRHEA;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA166123307;INSOMNIA;DISEASE;PA165816577;CYP2D6*2;HAPLOTYPE;
PA166123307;INSOMNIA;DISEASE;PA165816582;CYP2D6*10;HAPLOTYPE;
PA446970;POSTOPERATIVE NAUSEA AND VOMITING;DISEASE;PA165816576;CYP2D6*1;HAPLOTYPE;PD
PA446970;POSTOPERATIVE NAUSEA AND VOMITING;DISEASE;PA165988479;CYP2D6*1XN;HAPLOTYPE;PD
PA166169562;LAPAROSCOPIC SLEEVE GASTRECTOMY;DISEASE;PA165819201;CYP3A4*1;HAPLOTYPE;
PA166169562;LAPAROSCOPIC SLEEVE GASTRECTOMY;DISEASE;PA165819240;CYP3A4*18;HAPLOTYPE;
PA166169562;LAPAROSCOPIC SLEEVE GASTRECTOMY;DISEASE;PA165819244;CYP3A4*20;HAPLOTYPE;
PA166169562;LAPAROSCOPIC SLEEVE GASTRECTOMY;DISEASE;PA166048680;CYP3A4*22;HAPLOTYPE;
PA166169562;LAPAROSCOPIC SLEEVE GASTRECTOMY;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;
PA166169562;LAPAROSCOPIC SLEEVE GASTRECTOMY;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;
PA166129560;MAJOR ADVERSE CARDIAC EVENTS (MACE);DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA166129560;MAJOR ADVERSE CARDIAC EVENTS (MACE);DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;
PA166129560;MAJOR ADVERSE CARDIAC EVENTS (MACE);DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA166129560;MAJOR ADVERSE CARDIAC EVENTS (MACE);DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;
PA444255;GASTROESOPHAGEAL REFLUX;DISEASE;PA165816524;CYP2C19*8;HAPLOTYPE;
PA444255;GASTROESOPHAGEAL REFLUX;DISEASE;PA165816525;CYP2C19*9;HAPLOTYPE;
PA444255;GASTROESOPHAGEAL REFLUX;DISEASE;PA165816526;CYP2C19*10;HAPLOTYPE;
PA444255;GASTROESOPHAGEAL REFLUX;DISEASE;PA165816533;CYP2C19*17;HAPLOTYPE;
PA444255;GASTROESOPHAGEAL REFLUX;DISEASE;PA165816538;CYP2C19*24;HAPLOTYPE;
PA444255;GASTROESOPHAGEAL REFLUX;DISEASE;PA165816540;CYP2C19*26;HAPLOTYPE;
PA444255;GASTROESOPHAGEAL REFLUX;DISEASE;PA165980634;CYP2C19*1;HAPLOTYPE;PD
PA444255;GASTROESOPHAGEAL REFLUX;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;PD
PA444255;GASTROESOPHAGEAL REFLUX;DISEASE;PA165980636;CYP2C19*3;HAPLOTYPE;PD
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA165980635;CYP2C19*2;HAPLOTYPE;
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA166048675;GSTM1 NULL;HAPLOTYPE;
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA166048676;GSTM1 NON-NULL;HAPLOTYPE;
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA166048678;GSTT1 NULL;HAPLOTYPE;
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA166048679;GSTT1 NON-NULL;HAPLOTYPE;
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA166128213;CYP3A5*1;HAPLOTYPE;PD
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA166128219;CYP3A5*3;HAPLOTYPE;PD
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA166128233;CYP3A5*6;HAPLOTYPE;PD
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA166128234;CYP3A5*7;HAPLOTYPE;PD
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA166131619;NUDT15*1;HAPLOTYPE;
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA166131620;NUDT15*2;HAPLOTYPE;
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA166131621;NUDT15*3;HAPLOTYPE;
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA166131622;NUDT15*4;HAPLOTYPE;
PA166123007;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DISEASE;PA166131623;NUDT15*5;HAPLOTYPE;
